Search Result
Results for "
tissue selectivity
" in MedChemExpress (MCE) Product Catalog:
9
Biochemical Assay Reagents
8
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-115768
-
|
Poly-p-methoxyphenethylmethylamine
|
Phospholipase
|
Neurological Disease
Cancer
|
|
Compound 48/80 (Poly-p-methoxyphenethylmethylamine) is widely used in animal and tissue models as a "selective" mast cell activator. Compound 48/80 acts at the mast cell membrane to stimulate trimeric G-proteins and induces degranulation via phospholipase C and D pathways .
|
-
-
- HY-13738A
-
|
Keoxifene hydrochloride; LY156758; LY139481 hydrochloride
|
Estrogen Receptor/ERR
Autophagy
|
Endocrinology
Cancer
|
|
Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active estrogen receptor modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue .
|
-
-
- HY-13273
-
|
MK-2866; GTX-024; Enobosarm
|
Androgen Receptor
|
Others
Cancer
|
|
Ostarine (MK-2866) is a selective androgen receptor modulator (SARMs) that regulates cardiomyocyte function, improves bone healing, regulates uterine function, and influences muscle tissue metabolism .
|
-
-
- HY-B1614
-
-
-
- HY-120110
-
-
-
- HY-135747
-
|
GR-7
|
Bacterial
|
Infection
|
|
Gut restricted-7 (GR-7) is a potent, covalent and orally active pan-bile salt hydrolase (BSH) inhibitor. Gut restricted-7 has a tissue-selective and is restricted to the gut. Gut restricted-7 decreases gut bacterial BSHs and decreases deconjugated bile acid levels in feces of mice .
|
-
-
- HY-B1398
-
|
4-Aminophenazone
|
COX
Drug Metabolite
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Ampyrone (4-Aminophenazone; 4-Aminoantipyrine) is a reversible and low-damage optical clearing agent and non-selective COX inhibitor based on UV absorption properties. Ampyrone can improve the optical transmittance of mouse skin and other tissues. Ampyrone can induce tissue refractive index matching by enhancing UV absorption, reduce light scattering, and achieve tissue transparency in vivo. Ampyrone reduces the synthesis of prostaglandin PGE2, thereby exerting anti-inflammatory, analgesic and antipyretic effects. Ampyrone inhibits DNA damage, cell apoptosis and immune cell phagocytosis induced by Doxorubicin (HY-15142A) and Cisplatin (HY-17394), etc., and participates in the regulation of toxicity in tumor chemotherapy .
|
-
-
- HY-100186
-
|
|
Androgen Receptor
|
Cardiovascular Disease
Others
Metabolic Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
GSK-2881078 is an orally active and nonsteroidal selective androgen receptor modulator (SARM) which act as partial AR agonists in androgenic tissues while mainly as complete AR agonists in synthetic metabolic tissues,induces AR-mediated transcriptional activation in PC3(AR)2 cells (EC50 = 3.99 nM) and the effect can be inhibited by the non-steroidal AR antagonist Bicalutamide. GSK-2881078 can be used in research of muscle weakness and cachexia associated with both chronic and acute illness .
|
-
-
- HY-N0457A
-
|
(-)-Chicoric acid; trans-Caffeoyltartaric acid
|
HIV Integrase
HIV
Endogenous Metabolite
|
Infection
Cancer
|
|
L-Chicoric Acid ((-)-Chicoric acid) is a dicaffeoyltartaric acid and a potent, selective and reversible HIV-1 integrase inhibitor with an IC50 of ~100 nM. L-Chicoric Acid inhibits HIV-1 replication in tissue culture .
|
-
-
- HY-NP002D
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Bovine Serum Albumin (Biotinylated) is a biotinylated bovine serum albumin that selectively binds to different vascular subsets in lymphoid tissue. Bovine Serum Albumin (Biotinylated) can be used as a histochemical probe, and a targeting ligand for drug delivery .
|
-
-
- HY-111056
-
|
|
Ser/Thr Protease
|
Cancer
|
|
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50>100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion .
|
-
-
- HY-12023
-
GTx-007
4 Publications Verification
S-4
|
Androgen Receptor
|
Cancer
|
|
GTx-007 (S-4) is an orally active and selective nonsteroidal androgen receptor (AR) modulator (SARM) and a partial agonist, with Ki of 4 nM. GTx-007 (S-4) is identified as SARMs with potent and tissue-selective in vivo pharmacological activity .
|
-
-
- HY-110292
-
|
|
TRP Channel
Calcium Channel
|
Inflammation/Immunology
|
|
A-425619 is an orally active and selective transient receptor potential type V1 (TRPV1) antagonist. A-425619 blocks Capsaicin (HY-10448)- and N-arachidonoyl-dopamine (NADA)-induced Ca 2+ influx in dorsal root ganglia and trigeminal ganglia. A-425619 relieves pathophysiological pain associated with inflammation and tissue injury in rats. A-425619 can be used for the study of pain related to inflammation and tissue injury .
|
-
-
- HY-131881
-
|
|
mAChR
|
Neurological Disease
|
|
JHU37160 is a potent and brain-penetrant DREADD agonist, with EC50s of 18.5 nM and 0.2 nM for hM3Dq and hM4Di DREADDs in HEK-293 cells, respectively. JHU37160 exhibits selective [ 3H]Clozapine displacement from DREADDs and not from other Clozapine-binding sites in mice brain tissue .
|
-
-
- HY-12960
-
|
FLT3-IN-1
|
FLT3
c-Kit
Apoptosis
|
Cancer
|
|
SKLB4771 is a potent and selective Flt3 inhibitor with an IC50 value of 10 nM. SKLB4771 downregulates the phosphorylation of FLT3/STAT5/ERK, blocks cell proliferation, and induces apoptosis in tumor tissue .
|
-
-
- HY-101176
-
|
|
Melatonin Receptor
|
Cancer
|
|
2-Iodomelatonin is a potent agonist of melatonin receptor 1 (MT1) with a Ki value of 28 pM, it is more 5-fold selective for MT1 over MT2 . 2-iodomelatonin can be used to identify, characterize and localize melatonin binding sites in the brain and peripheral tissues .
|
-
-
- HY-103195
-
NKY80
2 Publications Verification
|
Adenylate Cyclase
|
Metabolic Disease
|
|
NKY80 is a potent, selective and non-competitive adenylyl cyclase (AC) type V isoform inhibitor with IC50s of 8.3 µM, 132 µM and 1.7 mM for type V, III and II, respectively. NKY80 is a non-nucleoside quinazolinone and regulates the AC catalytic activity in heart and lung tissues .
|
-
-
- HY-D0053
-
|
6-Carboxy-X-rhodamine
|
Fluorescent Dye
|
Others
|
|
6-ROX is a selective fluorescent probe and potential inhibitor of COX-2. 6-ROX binds to the active site of COX-2 and inhibits its conversion of arachidonic acid into prostaglandins. 6-ROX is often used in the field of optical imaging related to tumors and inflammation, and helps detect diseased tissues with high expression of COX-2 .
|
-
-
- HY-14210
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
TNAP-IN-1 (Compound 1) is a selective tissue-nonspecific alkaline phosphatase (TNAP) inhibitor, with an IC50 of 0.19 μM. TNAP-IN-1 can be used for the research of soft tissue calcification .
|
-
-
- HY-119649
-
|
IKI220
|
Environmental Pollutants
Parasite
|
Infection
|
|
Flonicamid (IKI220) is a novel systemic insecticide with selective activity against hemipterous pests. The main insecticidal mechanism of flonicamid is starvation based on the inhibition of stylet penetration to plant tissues .
|
-
-
- HY-P10216
-
|
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
CAQK peptide selectively binds to injured mouse brain. CAQK peptide selectively targets demyelinating areas and it is absent from healthy tissue. The CAQK peptide target is a proteoglycan complex upregulated in brain injuries and is used for drug delivery. CAQK peptide can penetrate the blood-brain barrier .
|
-
-
- HY-134194
-
KL201
2 Publications Verification
|
Cryptochrome
|
Metabolic Disease
|
|
KL201 a circadian clock modulator, is a isoform-selective cryptochrome 1 (CRY1) stabilizer. KL201 has no stabilizing effect on CRY2. KL201 lengthens the period of circadian rhythms in cells and tissues .
|
-
-
- HY-120017
-
|
MD-370503
|
Monoamine Oxidase
|
Neurological Disease
|
|
Befloxatone (MD-370503) is an orally active, selective and reversible inhibitor of Monoamine Oxidase A (MAO-A) (IC50=4 nM). Befloxatone increases the tissue level of monoamine, striatal dopamine and cortical norepinephrine. Befloxatone has antidepressant potential .
|
-
-
- HY-151425
-
|
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
TDO-IN-1 is an orally active and selective inhibitor of tryptophan 2,3-dioxygenase (TDO), shows excellent selectivity over indoleamine-2,3-dioxygenase (IDO), with an IC50 value of 0.62 μM (IDO). TDO-IN-1 reverse the local immune tolerance of tumor tissue to inhibit tumor growth in vivo .
|
-
-
- HY-172663A
-
|
|
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
Trabectedin derivative 1 TFA is a selective DNA minor groove binder. Trabectedin derivative 1 TFA inhibits DNA transcription and repair to induce tumor cell apoptosis. Trabectedin derivative 1 TFA is promising for research of solid tumors such as soft tissue sarcoma and ovarian cancer .
|
-
-
- HY-173527
-
|
|
Mitochondrial Metabolism
|
Metabolic Disease
|
|
PSSI-51 is an orally active, peripherally selective inhibitor of succinyl-CoA:3-ketoacid-CoA transferase (SCOT). PSSI-51 inhibits SCOT activity in peripheral tissues (such as muscle and kidney) but does not affect SCOT activity in brain tissue. PSSI-51 reduces ketone body oxidation by inhibiting SCOT, thereby improving obesity-related hyperglycemia. PSSI-51 can be used in the study of type 2 diabetes (T2D) and has the potential to improve obesity-related metabolic disorders .
|
-
-
- HY-W020468
-
|
DuP 996
|
Potassium Channel
TRP Channel
|
Neurological Disease
|
|
Linopirdine (DuP 996) is an orally active, selective M-type K + current (IM; Kv7; KCNQ Channels) inhibitor with an IC50 of 2.4 μM. Linopirdine is a TRPV1 agonist. Linopirdine, a putative cognition enhancing agent, increases acetylcholine release in rat brain tissue .
|
-
-
- HY-18102
-
|
|
Androgen Receptor
|
Neurological Disease
|
|
GLPG0492 is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy .
|
-
-
- HY-119433
-
|
J867
|
Progesterone Receptor
|
Endocrinology
|
|
Asoprisnil (J867), a selective progesterone receptor modulator, exhibits mixed progesterone agonist and antagonist effects on various progesterone targeted tissues in animal and human .
|
-
-
- HY-13556A
-
|
LY353381 hydrochloride; SERM III hydrochloride
|
Estrogen Receptor/ERR
|
Cancer
|
|
Arzoxifene (LY353381) hydrocloride is a selective estrogen receptor modulator that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol.
|
-
-
- HY-145310
-
|
|
Epigenetic Reader Domain
|
Inflammation/Immunology
|
|
ZL0590 is a potent, orally active BRD4 BD1-selective inhibitor with an IC50 of 90 nM for human BRD4 BD1. ZL0590 exhibits significant anti-inflammatory activities. ZL0590 can reduce mucosal inflammation in animal models of inflammatory bowel disease and restores tissue architecture. ZL0590 can be used in research on inflammatory diseases such as inflammatory bowel disease .
|
-
-
- HY-137976
-
|
Penequinine hydrochloride
|
mAChR
NF-κB
Apoptosis
Autophagy
Akt
GSK-3
ERK
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Penehyclidine (Penequinine) hydrochloride, a anticholinergic agent, is a selective antagonist of M1 and M3 receptors. Penehyclidine hydrochloride activates NF-kβ in lung tissue and inhibits the release of inflammatory factors. Penehyclidine hydrochloride can alleviate the pulmonary inflammatory response in rats with chronic obstructive pulmonary disease (COPD) undergoing mechanical ventilation .
|
-
-
- HY-175728
-
|
|
Potassium Channel
Sodium Channel
Calcium Channel
|
Metabolic Disease
|
|
VU6032735 is a potent and subtype-selective sperm-specific potassium channel 3 (SLO3) inhibitor with IC50 values of 165 nM (hSLO3) and 730 nM (mSLO3). VU6032735 also inhibits sodium channel and L-type calcium channel VU6032735 can sustain high tissue exposure in the fertilized oviduct. VU6032735 can be used for the research of contraception .
|
-
-
- HY-U00178
-
-
-
- HY-W062700
-
-
-
- HY-131006
-
|
|
Monoamine Transporter
|
Neurological Disease
|
|
FFN200 dihydrochloride, a fluorescent substrate of VMAT2, selectively trace monoamine exocytosis in both neuronal cell culture and brain tissue. The fluorescence excitation and emission maxima of FFN200 are determined to be 352 and 451 nm, respectively .
|
-
-
- HY-P1473
-
|
Amylin (8-37) (mouse, rat)
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (8-37), rat is a truncated analog of native Amylin that selectively inhibits insulin-related glucose uptake and glycogen deposition in muscle tissue. Amylin (8-37), rat is a weak amylin receptor (AMY) antagonist.
|
-
-
- HY-13738AR
-
|
Keoxifene hydrochloride(Standard); LY156758(Standard); LY139481 hydrochloride (Standard)
|
Reference Standards
Estrogen Receptor/ERR
Autophagy
|
Endocrinology
Cancer
|
|
Raloxifene (hydrochloride) (Standard) is the analytical standard of Raloxifene (hydrochloride). This product is intended for research and analytical applications. Raloxifene hydrochloride (Keoxifene hydrochloride) is a second generation selective and orally active estrogen receptor modulator. Raloxifene hydrochloride produces estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue .
|
-
-
- HY-131891
-
|
|
mAChR
|
Neurological Disease
|
|
JHU37152 is a potent and brain-penetrant DREADD agonist, with EC50s of 5 nM and 0.5 nM for hM3Dq and hM4Di DREADDs in HEK-293 cells, respectively. JHU37152 exhibits selective [ 3H]Clozapine displacement from DREADDs and not from other Clozapine-binding sites in mice brain tissue .
|
-
-
- HY-117658
-
|
|
MAP3K
|
Cardiovascular Disease
|
|
GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC50= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC50= 1 μM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue .
|
-
-
- HY-N9141
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
Nantenine is a serotonergic receptor antagonist. Nantenine selectively inhibits the contractile response of tissues to serotonin. Nantenine can be isolated from Nandina domestica .
|
-
-
- HY-130013
-
|
|
Fluorescent Dye
|
Others
|
|
HKYellow-AM (6/12-mixture) is a yellow fluorescent probe that can detect ONOO- in living cells and tissues with high selectivity and sensitivity without cytotoxicity .
|
-
-
- HY-163684
-
|
|
Complement System
|
Inflammation/Immunology
|
|
Zoracopan is a selective complement factor D (CFD) inhibitor. When administered systemically (orally or intravenously), Zoracopan accumulates and is sustained-released in ocular tissues, primarily in the choroid-retinal pigment epithelium (C-RPE) and/or iridociliary body (I-CB) .
|
-
-
- HY-D1275
-
|
|
Fluorescent Dye
|
Others
|
|
CAY10731 (compound 3) is a highly selective fluorescent probe for detection of hydrogen sulfide (H2S). CAY10731 is used to monitor exo- and endogenous H2S in both cancer and normal cells. CAY10731 is applied for imaging of H2S in living tissues at variable depths and in nematodes .
|
-
-
- HY-19665
-
|
LY303870
|
Neurokinin Receptor
|
Neurological Disease
Inflammation/Immunology
|
|
Lanepitant (LY303870) is a selective neurokinin-1 (NK-1) receptor antagonist. Lanepitant blocks neurogenic inflammation and pain transmission by preventing the binding of substance P to NK-1 receptors on both neuronal and non-neuronal tissues. Lanepitant can be used to study osteoarthritis .
|
-
-
- HY-B1398R
-
|
4-Aminophenazone (Standard)
|
Reference Standards
COX
Drug Metabolite
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Ampyrone (4-Aminophenazone) (Standard) is the analytical standard of Ampyrone (HY-B1398). This product is intended for research and analytical applications. Ampyrone (4-Aminophenazone; 4-Aminoantipyrine) is a reversible and low-damage optical clearing agent and non-selective COX inhibitor based on UV absorption properties. Ampyrone can improve the optical transmittance of mouse skin and other tissues. Ampyrone can induce tissue refractive index matching by enhancing UV absorption, reduce light scattering, and achieve tissue transparency in vivo. Ampyrone reduces the synthesis of prostaglandin PGE2, thereby exerting anti-inflammatory, analgesic and antipyretic effects. Ampyrone inhibits DNA damage, cell apoptosis and immune cell phagocytosis induced by Doxorubicin (HY-15142A) and Cisplatin (HY-17394), etc., and participates in the regulation of toxicity in tumor chemotherapy .
|
-
-
- HY-119649S
-
|
IKI220-15N18O
|
Isotope-Labeled Compounds
Parasite
|
Infection
|
|
Flonicamid- 15N,18O (IKI220- 15N,18O) is 15N labeled Flonicamid. Flonicamid (IKI220) is a novel systemic insecticide with selective activity against hemipterous pests. The main insecticidal mechanism of flonicamid is starvation based on the inhibition of stylet penetration to plant tissues .
|
-
-
- HY-105318
-
|
|
Androgen Receptor
|
Metabolic Disease
Endocrinology
|
|
LGD-2226 is a selective and orally active androgen receptor modulator with an EC50 of 0.2 nM and a Ki of 1.5 nM for human androgen receptor. LGD-2226 shows tissue selectivity in animal models, with reduced effects on prostate compared to muscle. LGD-2226 can be used for muscle wasting, osteoporosis and sexual dysfunction .
|
-
-
- HY-14360
-
|
|
Cathepsin
|
Metabolic Disease
|
|
MK 1256 is a highly selective and orally active inhibitor of tissue protease K (Cat K) with an IC50 of 0.62 nM. MK 1256 shows extremely high selectivity towards other tissue proteases (all > 1100 times), with only a slightly lower selectivity for tissue protease F (Cat F) (110 times). MK 1256 exhibits strong anti-bone resorption activity in the osteoporosis model of rhesus monkeys with ovariectomy. MK 1256 can be used for research on osteoporosis .
|
-
-
- HY-135732
-
|
|
Androgen Receptor
|
Cancer
|
|
SK33, a trifluoromethylated enobosarm analog, is a potent, and tissue selective anti-androgen. SK33reduces androgen receptor (AR) transcriptional activity .
|
-
- HY-122331
-
-
- HY-15132
-
|
|
Ser/Thr Protease
|
Inflammation/Immunology
|
|
MOL-6131 is a highly selective, reversible tryptase inhibitor, with a Ki of 45 nM. MOL-6131 significantly reduces the following features of allergic airway inflammation: eosinophil infiltration in lung tissue, goblet cell hyperplasia and mucus occlusion of airways .
|
-
- HY-150970
-
|
|
Pyroptosis
|
Cancer
|
|
ICy-OH, an iodinated photosensitizer, is an effective anticancer agent. ICy-OH can be used not only for deep tissue imaging (λex=640 nm，λem=690-740 nm) but also to selectively induce cell death in pancreatic cancer cells via cell pyroptosis pathway .
|
-
- HY-155684
-
|
|
PROTACs
VEGFR
PDGFR
Ephrin Receptor
|
Cancer
|
|
SA-PA is an intracellular self-assembled PROTAC based on azide and alkyne. SA-PA is able to selectively degrade VEGFR-2, PDGFR-β and EphB4 proteins in U87 cells. SA-PA can be converted to PROTAC in situ by click reaction with the help of endogenous copper in tumor tissues .
|
-
- HY-114218
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
Inflammation/Immunology
|
|
BL-122 is a selective phosphodiesterase-5 (PDE-5) inhibitor. BL-122 can increase the level of cGMP in the tissue, promote the expression of nitric oxide (NO), and mediate the relaxation of smooth muscle. BL-122 can be used for the researches of inflammation, immunology and cardiovascular disease, such as asthma and hypertension .
|
-
- HY-103336
-
|
T1117
|
GPR55
Cannabinoid Receptor
|
Cardiovascular Disease
|
|
Tocrifluor 1117 (T1117), a fluorescent form of the cannabinoid CB1 receptor antagonist AM251 (HY-15443), is a selective fluorescent GPR55 ligand. Tocrifluor 1117 is a potent tool for identifying the cellular location of cannabinoid receptors (including GPR55 in living tissues) (Ex/Em=543/590 nm) .
|
-
- HY-111056A
-
|
|
Ser/Thr Protease
|
Cancer
|
|
UK122 hydrochloride is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC50 of 0.2 μM. UK122 hydrochloride shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC50s > 100 μM). UK122 hydrochloride, a 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion .
|
-
- HY-U00216
-
-
- HY-115768A
-
|
Poly-p-methoxyphenethylmethylamine (trimer)
|
Phospholipase
|
Others
|
|
Compound 48/80 (trimer) is a trimer of Compound 48/80 (HY-115768). Compound 48/80 is widely used in animal and tissue models as a "selective" mast cell activator .
|
-
- HY-126969
-
|
|
PPAR
|
Metabolic Disease
|
|
C333H is a selective PPARγ modulator with insulin-sensitizing and hypoglycemic activities. C333H exhibits similar insulin-sensitizing effects to thiazolidinediones (TZDs) in diabetic mouse models without significantly increasing body weight or adipose tissue weight. C333H increases circulating high molecular weight adiponectin isoform levels in diabetic db/db mice, reduces serine phosphorylation of PPARγ 273 in brown adipose tissue, and selectively modulates the expression of specific PPARγ target genes in adipose tissue. Express. C333H exhibits weak recruitment of co-activators and weak dissociation of co-repressors in vitro. These properties suggest that C333H may be a potential inhibitor of type 2 diabetes .
|
-
- HY-N2304A
-
|
|
Opioid Receptor
|
Inflammation/Immunology
|
|
Methyl-6-alpha-Naltrexol is a metabolite of Methylnaltrexone (MNTX). Methylnaltrexone is a selective mu-opioid receptor antagonist and functions as a peripherally acting receptor antagonist in tissues of the gastrointestinal tract .
|
-
- HY-161835
-
-
- HY-114056
-
|
|
Others
|
Cancer
|
|
AS115 is a potent and selective KIAA1363 inactivator with IC50 value of 150 nM. KIAA1363 is a 2-acetyl monoacylglycerol ether (MAGE) hydrolase that is upregulated in aggressive cancers of various tissues .
|
-
- HY-163146
-
|
|
Fluorescent Dye
|
Cancer
|
|
TME-HYM (PH Probe) is a novel fluorescent probe based on acidic tumor microenvironment (TME) activation and organic anion transporting polypeptide (OATPs, overexpressed on cancer cells), and can be selective uptaken. TME-HYM (PH Probe) can selectively lit up cancer cells and tumor tissues, offering dual tumor selectivity for precise visualization of tumor mass .
|
-
- HY-120290
-
|
|
Histone Acetyltransferase
|
Cancer
|
|
PU141 is a selected pyridoisothiazolone HAT inhibitor. PU141 is selective toward CBP and p300. PU141 induces cellular histone hypoacetylation and inhibits growth of several neoplastic cell lines originating from different tissues. Anticancer activity .
|
-
- HY-172687A
-
|
|
Liposome
|
Cardiovascular Disease
|
|
DSPE-PEG3400-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG3400-CSTSMLKAC can be used for drug delivery .
|
-
- HY-172688
-
|
|
Liposome
|
Cardiovascular Disease
|
|
DSPE-PEG5000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG5000-CSTSMLKAC can be used for drug delivery .
|
-
- HY-119649R
-
|
IKI220 (Standard)
|
Parasite
Reference Standards
|
Infection
|
|
Flonicamid (Standard) is the analytical standard of Flonicamid. This product is intended for research and analytical applications. Flonicamid (IKI220) is a novel systemic insecticide with selective activity against hemipterous pests. The main insecticidal mechanism of flonicamid is starvation based on the inhibition of stylet penetration to plant tissues .
|
-
- HY-147374
-
|
|
Epigenetic Reader Domain
|
Metabolic Disease
Inflammation/Immunology
|
|
Bromodomain inhibitor-9 is a Bromodomains inhibitor that selectively inhibits BRD4-1 (Kd: 12 nM). Bromodomain inhibitor-9 can be used in the research of diseases or conditions associated with systemic or tissue inflammation, lipid metabolism, fibrosis or chronic autoimmune diseases .
|
-
- HY-179011
-
|
|
Cytochrome P450
|
Metabolic Disease
|
|
CYP3A4-IN-6 (Compound 8a) is a CYP3A4 inhibitor with tissue-selective metabolism. CYP3A4-IN-6 remains stable in the intestinal S9 component but is rapidly metabolized in the liver S9 component, forming a less active metabolite. CYP3A4-IN-6 can be used for intestinal selectivity studies .
|
-
- HY-142119
-
|
|
mAChR
NF-κB
|
Inflammation/Immunology
|
|
Penehyclidine, a anticholinergic agent, is a selective antagonist of M1 and M3 receptors. Penehyclidine activates NF-kβ in lung tissue and inhibits the release of inflammatory factors. Penehyclidine can alleviate the pulmonary inflammatory response in rats with chronic obstructive pulmonary disease (COPD) undergoing mechanical ventilation .
|
-
- HY-N0457AR
-
|
(-)-Chicoric acid (Standard); trans-Caffeoyltartaric acid (Standard)
|
Reference Standards
HIV Integrase
HIV
Endogenous Metabolite
|
Infection
Cancer
|
|
L-Chicoric Acid (Standard) is the analytical standard of L-Chicoric Acid. This product is intended for research and analytical applications. L-Chicoric Acid ((-)-Chicoric acid) is a dicaffeoyltartaric acid and a potent, selective and reversible HIV-1 integrase inhibitor with an IC50 of ~100 nM. L-Chicoric Acid inhibits HIV-1 replication in tissue culture .
|
-
- HY-W020468R
-
|
DuP 996 (Standard)
|
Reference Standards
Potassium Channel
TRP Channel
|
Neurological Disease
|
|
Linopirdine (DuP 996) is an orally active, selective M-type K+ current (IM; Kv7; KCNQ Channels) inhibitor with an IC50 of 2.4 μM. Linopirdine is a TRPV1 agonist. Linopirdine, a putative cognition enhancing agent, increases acetylcholine release in rat brain tissue .
|
-
- HY-B1398S
-
|
4-Aminoantipyrine-d3
|
Isotope-Labeled Compounds
COX
Drug Metabolite
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Ampyrone-d3 is the deuterium labeled Ampyrone (HY-B1398). Ampyrone (4-Aminophenazone; 4-Aminoantipyrine) is a reversible and low-damage optical clearing agent and non-selective COX inhibitor based on UV absorption properties. Ampyrone can improve the optical transmittance of mouse skin and other tissues. Ampyrone can induce tissue refractive index matching by enhancing UV absorption, reduce light scattering, and achieve tissue transparency in vivo. Ampyrone reduces the synthesis of prostaglandin PGE2, thereby exerting anti-inflammatory, analgesic and antipyretic effects. Ampyrone inhibits DNA damage, cell apoptosis and immune cell phagocytosis induced by Doxorubicin (HY-15142A) and Cisplatin (HY-17394), etc., and participates in the regulation of toxicity in tumor chemotherapy .
|
-
- HY-106404
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
RPR 130737 is a selective, potent and competitive inhibitor for factor Xa with a Ki of 2.4 nM. RPR 130737 shows selectivity of more than 1000-fold over thrombin, activated protein C, plasmin, tissue-plasminogen activator and trypsin. RPR 130737 can prolong plasma activated partial thromboplastin time and prothrombin time. RPR 130737 shows no effect on platelet aggregation. RPR 130737 can be used for the research of cardiovascular disease, such as thrombosis .
|
-
- HY-19409
-
|
|
Calcium Channel
|
Neurological Disease
|
|
AJG049 is a novel antagonist of the Ca 2+ channel with an IC50 value of 79 nM. AJG049 can be used to reduce the contraction of intestinal smooth muscle .
|
-
- HY-144126
-
|
|
LPL Receptor
|
Inflammation/Immunology
|
|
S1P1 agonist 5 is a selective and orally active S1P1 agonist. S1P1 agonist 5 inhibits the lymphocyte egress from the lymphoid tissue to the peripheral blood. S1P1 agonist 5 has the potential for the research of multiple sclerosis (MS) .
|
-
- HY-131340
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
LASSBio-1632 is a new anti-asthmatic lead candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-α production in the lung tissue. LASSBio-1632 (7j) displays high experimental BBB permeability across BBB through passive diffusion .
|
-
- HY-167689
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
|
Parethoxycaine hydrochloride is an anesthetic with nerve conduction blocking activity. Parethoxycaine hydrochloride exhibits non-selective inhibitory effects on responses to various stimulants in rat vas deferens and guinea pig ileum muscles. Parethoxycaine hydrochloride has an enhanced effect on the action of norepinephrine, and its methyl bromide derivative also exhibits the same properties on the action of norepinephrine and potassium ions. Derivatives of parethoxycaine hydrochloride have significant effects on calcium dose-response curves, displaying different tissue and stimulant selectivities. The mechanism of action of Parethoxycaine hydrochloride involves the regulation of calcium transport processes .
|
-
- HY-B1614R
-
|
NAB-365 hydrochloride (Standard)
|
Reference Standards
Adrenergic Receptor
|
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
|
Clenbuterol (hydrochloride) (Standard) is the analytical standard of Clenbuterol (hydrochloride). This product is intended for research and analytical applications. Clenbuterol (NAB-365) hydrochloride, a selective β2-adrenergic agonist, enhances skeletal muscle strength and hypertrophy. Clenbuterol hydrochloride induces growth factor mRNA, activates astrocytes, and protects rat brain tissue against ischemic damage .
|
-
- HY-155685
-
|
|
PROTACs
VEGFR
Ephrin Receptor
Apoptosis
|
Cancer
|
|
SA-VA is an intracellular self-assembled PROTAC based on azide and alkyne. SA-VA is able to selectively degrade VEGFR-2 and EphB4 proteins in U87 cells. SA-VA can be converted to PROTAC in situ by click reaction with the help of endogenous copper in tumor tissues. SA-VA promotes apoptosis and blocks cells in S phase .
|
-
- HY-W753375R
-
|
|
Reference Standards
Fungal
Succinate Dehydrogenase
|
Infection
|
|
Clenbuterol (hydrochloride) (Standard) is the analytical standard of Clenbuterol (hydrochloride). This product is intended for research and analytical applications. Clenbuterol (NAB-365) hydrochloride, a selective β2-adrenergic agonist, enhances skeletal muscle strength and hypertrophy. Clenbuterol hydrochloride induces growth factor mRNA, activates astrocytes, and protects rat brain tissue against ischemic damage .
|
-
- HY-171248
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cardiovascular Disease
Endocrinology
|
|
CDD-1115 is a potent, selective inhibitor of BMPR2 with IC50 of 1.8 nM, Kiapp of 6.2 nM. CDD-1115 inhibits bone morphogenetic protein (BMP)-mediated gene expression. BMP controls cellular processes across many tissue types, including the kidney, skeletal muscle, heart, and reproductive organs. BMP induces ectopic bone formation .
|
-
- HY-171249
-
|
|
TGF-β Receptor
|
Cardiovascular Disease
Endocrinology
|
|
CDD-1431 is a low-nanomolar selective kinase inhibitors of BMPR2, with Kiapp value of 20.6 nM. CDD-1431 suppresses BRE-reporter activity, with an IC50 of 4.87 μM. BMP controls cellular processes across many tissue types, including the kidney, skeletal muscle, heart, and reproductive organs. BMP induces ectopic bone formation .
|
-
- HY-105318R
-
|
|
Reference Standards
Androgen Receptor
|
Metabolic Disease
Endocrinology
|
|
LGD-2226 (Standard) is the analytical standard of LGD-2226 (HY-105318). This product is intended for research and analytical applications. LGD-2226 is a selective and orally active androgen receptor modulator with an EC50 of 0.2 nM and a Ki of 1.5 nM for human androgen receptor. LGD-2226 shows tissue selectivity in animal models, with reduced effects on prostate compared to muscle. LGD-2226 can be used for muscle wasting, osteoporosis and sexual dysfunction .
|
-
- HY-U00178R
-
-
- HY-119436
-
|
|
Androgen Receptor
|
Metabolic Disease
|
|
LG-120907 is a selective androgen receptor (AR) antagonist with a Ki value of 26 nM. LG-120907 inhibits Testosterone-induced increases in ventral prostate (VP) tissue weight and seminal vesicles (SV) tissue weight in vivo .
|
-
- HY-D3267
-
|
|
Fluorescent Dye
|
Others
|
|
ACu1 is a copper (I)-selective two-photon fluorescent probe that enables the visual imaging of Cu + distribution in living cells and tissues .
|
-
- HY-W713888
-
|
|
Fluorescent Dye
|
Others
|
|
Aniline blue diammonium is a component of commonly used polychrome stains. Aniline blue diammonium is used to stain collagen fibers in tissue sections using Masson′s trichrome protocol for staining multiple components. Collagen is stained blue by this method. The dye is suitable for selective staining of callose in plant specimens and staining histones for assessing nuclear maturity. Aniline blue diammonium is used in Gomori′s one-step trichrome stain and Mallory′s connective tissue stain for tissue including kidney and intestine.
|
-
- HY-120130
-
|
|
RAR/RXR
|
Cancer
|
|
BMS-948 is a RARβ-selective transcriptional agonist with an EC50 of 0.1 μM. BMS-948 is used in the research of tumor diseases, embryonic development and tissue remodeling .
|
-
- HY-D3247
-
|
|
Fluorescent Dye
|
Others
|
|
Cobalt (II) plant dye (Compound 3) is a Cobalt (II) probe. Cobalt (II) plant dye is used for the selective detection of bioaccumulated Cobalt (II) ions in root and stem tissues of Hybanthus enneaspermus plants .
|
-
- HY-D3172
-
|
|
Fluorescent Dye
|
Metabolic Disease
|
|
BD-105 is a glucagon-binding fluorescent probe with a Ka value of 13.3 μM. BD-105 exhibits changes in fluorescence intensity upon interaction with glucagon, and colocalizes with glucagon in cells and tissues. BD-105 is a selective cell stain that labels glucagon-secreting cells without staining insulin-secreting cells or non-endocrine control cells. BD-105 serves as an imaging reagent for glucagon in live cells and tissues .
|
-
- HY-119058
-
|
CP-744809
|
Aldose Reductase
|
Metabolic Disease
|
|
ARI-809 (CP-744809) is a highly selective, orally active aldose reductase inhibitor with an IC50 of 1 nM. ARI-809 blocks excessive glucose flux through the polyol pathway. ARI-809 normalizes elevated sorbitol and fructose levels in sciatic nerve tissues of diabetic rat models, inhibits sorbitol accumulation in lens tissues, and brings elevated urinary albumin excretion close to normal. ARI-809 can be used in diabetes research .
|
-
- HY-172686
-
|
|
Liposome
|
Cardiovascular Disease
|
|
DSPE-PEG1000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG1000-CSTSMLKAC can be used for drug delivery .
|
-
- HY-181774
-
|
|
Phosphodiesterase (PDE)
|
Endocrinology
|
|
PDE4/5-IN-1 is a selective phosphodiesterase 4/5 (PDE4/5) dual inhibitor. PDE4/5-IN-1 functionally inhibits PDE5, PDE4B2, and PDE4D2 activity. PDE4/5-IN-1 relaxes isolated rat prostate tissue, enhances nitric oxide-induced relaxation in isolated rat prostate tissue, and reduces alpha-1 adrenoceptor-mediated contractile responses in isolated rat prostate tissue. PDE4/5-IN-1 inhibits proliferation of human hyperplastic prostate cells. PDE4/5-IN-1 can be used for the research of benign prostatic hyperplasia .
|
-
- HY-D3211
-
|
|
Fluorescent Dye
Apoptosis
Autophagy
|
Cancer
|
|
HJTA is a selective, pH/GSH dual-responsive Fluorescent probe and anticancer agent. HJTA selectively undergoes an enzymatic reaction with GSTπ. HJTA induces Apoptosis and Autophagy by regulating the expression of apoptotic and autophagic proteins. HJTA exhibits pH- and GSH-dual-responsive fluorescence in tumor cells. HJTA selectively illuminates tumor tissues, enabling precise in situ visualization of colon tumors. HJTA exerts anticancer effects against colon cancer. HJTA can be used for colon cancer research .
|
-
- HY-P11590
-
|
|
EGFR
|
Cancer
|
|
WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a KD of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .
|
-
- HY-181427
-
|
|
Androgen Receptor
|
Cancer
|
|
UT-143 is an orally active, selective irreversible covalent antagonist of androgen receptor (AR). UT-143 inhibits the proliferation of AR-positive prostate cancer cells, reduces the weight of androgen target tissues in rats, and suppresses the growth of AR-positive xenograft tumors. UT-143 can be used for the research of prostate cancer .
|
-
- HY-19938
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
MTL-005 is a boron-containing radiosensitizer used in Boron Neutron Capture Therapy (BNCT). MTL-005 enriches the boron-10 isotope in tumor tissues, causing nuclear fission under thermal neutron irradiation, releasing high linear energy transfer (LET) α particles and lithium ions, which selectively destroy tumor cells while minimizing damage to surrounding normal tissues. MTL-005 significantly controlls the tumor progression in the SCCVII squamous cell carcinoma mouse model and prolonged the survival of the mice. MTL-005 can be used to study solid tumors such as head and neck cancer.
|
-
- HY-N9980
-
|
|
PI3K
Akt
NF-κB
p38 MAPK
AP-1
|
Inflammation/Immunology
|
|
Antcin K is a selective inhibitor targeting the PI3K/Akt, NF-κB, MEK1/2-ERK, p38 and AP-1 pathways. Antcin K upregulates IL-10 expression, thereby inhibiting the production of pro-inflammatory factors, blocking monocyte adhesion, reducing tissue damage, and promoting myogenesis. Antcin K has significant anti-inflammatory, anti-damage and tissue protective activities. Antcin K is mainly used in the research of inflammation-related diseases such as periodontitis, rheumatoid arthritis, and skeletal muscle injury .
|
-
- HY-149708
-
|
|
ICMT
|
Others
|
|
UCM-13207 is a selective isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor with a human IC50 of 1.4 μM and human Ka of 7.2 μM. UCM-13207 modulates progerin localization, stability, and levels, reduces DNA damage, increases cellular viability, and decreases tissue senescence. UCM-13207 can be used for the research of Hutchinson−Gilford progeria syndrome .
|
-
- HY-10656
-
|
|
Urotensin Receptor
|
Inflammation/Immunology
|
|
SB-657510 is a selective urotensin II (UII) receptor (UT) antagonist. The Ki values are 61, 17, 30, 65 and 56 nM for human, monkey, cat, rat and mouse receptors, respectively. SB-657510 exerts anti-inflammatory effects by inhibiting UII-induced upregulation of inflammatory mediators such as adhesion molecules, cytokines, and tissue factor in human vascular endothelial cells .
|
-
- HY-131334
-
|
|
AMPK
|
Metabolic Disease
|
|
AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .
|
-
- HY-120972
-
|
|
Fluorescent Dye
|
Others
|
|
Pentafluorobenzenesulfonyl fluorescein is a H2O2-selective sensor that can be used to detect H2O2 levels in cells. Pentafluorobenzenesulfonyl fluorescein is generally non-fluorescent, but emits fluorescence when its sulfonyl bond undergoes perhydrolysis by H2O2 . Pentafluorobenzenesulfonyl fluorescein undergoes slight cleavage of its sulfonate ester bond by [Cu (phen)2] 2+, and can detect hydrogen peroxide around the ablation sites of fin tissues and keratinocytes in zebrafish larvae .
|
-
- HY-137561A
-
|
PLN-74809 hydrochloride
|
Integrin
|
Inflammation/Immunology
|
|
Bexotegrast hydrochloride (PLN-74809 hydrochloride) is a small molecule dual selective inhibitor with activity targeting αVβ1 and αVβ6. Bexotegrast hydrochloride is used for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast hydrochloride inhibits the activation of TGF-β1 by blocking the function of these integrins, thereby preventing the growth of fibrous tissue in the lungs and bile ducts .
|
-
- HY-10569
-
|
ACT-128800
|
LPL Receptor
|
Inflammation/Immunology
|
|
Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .
|
-
- HY-105017
-
|
ATL 313; DE 112
|
Adenosine Receptor
|
Infection
Inflammation/Immunology
|
|
Evodenoson is a selective agonist of the A2A adenosine receptor. Evodenoson’s primary actions include reducing inflammatory responses, decreasing intestinal fluid secretion, edema, tissue damage, and neutrophil infiltration induced by Clostridium difficile toxin A. Evodenoson’s protective effect is achieved by reducing myeloperoxidase (MPO) and adenosine deaminase (ADA) activities, and by lowering the production of tumor necrosis factor-alpha (TNF-α) .
|
-
- HY-10862
-
|
Benzothiazole analog 3
|
FAAH
Autophagy
|
Neurological Disease
Cancer
|
FAAH inhibitor 1 (compound 3) is a selective reversible FAAH inhibitor. FAAH inhibitor 1 has no off-target activity with respect to other serine hydrolases. FAAH inhibitor 1 is exclusively specific against FAAH in rat brain with an IC50 value of 18 nM and had no missing protein bands in all the other tissues. FAAH inhibitor 1 can be used for neurological disorders research .
|
-
- HY-19674
-
|
SSR182289A free base
|
Thrombin
|
Cardiovascular Disease
|
|
SSR182289 (SSR182289A free base) is a selective and potent orally active thrombin inhibitor. SSR182289 competitively and selectivity inhibits human thrombin (Ki=0.031 μM). SSR182289 demonstrates anticoagulant activity in vitro (thrombin time EC100=96 nM) and inhibits tissue factor-induced thrombin generation (IC50=0.15 μM) in human plasma. SSR182289 inhibits thrombin-induced aggregation of human platelets (IC50=32 nM), but has no effect on aggregation induced by other platelet agonists .
|
-
- HY-116450
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
TISCH is a potent and selective iodinated ligand with high affinity and selectivity for CNS D1 dopamine receptors. TISCH showed a Kd value of 0.205 nM in rat striatal tissue, indicating its effectiveness in biological activity. TISCH is able to easily cross the blood-brain barrier and show distribution in specific areas with D1 receptor density. TISCH is considered to be useful as a pharmacological tool for characterizing D1 dopamine receptors. When labeled with I-123, TISCH has the potential to be used as an in vivo imaging agent for CNS D1 dopamine receptors .
|
-
- HY-16923A
-
|
BIII-890 hydrochloride; BIII-890 CL
|
Sodium Channel
|
Neurological Disease
|
|
Crobenetine hydrochloride (BIII-890 hydrochloride) is the hydrochloride form of Crobenetine (HY-16923). Crobenetine hydrochloride is a selective inhibitor for Na + channel. Crobenetine hydrochloride displaces 3HBTX from site 2 of the Na + channel (IC50=49 nM) in rat brain synaptosomes, exhibits only low binding affinity for other receptors and ion channels. Crobenetine hydrochloride protects brain tissue from the deleterious effects of focal cerebral ischemia in rodents .
|
-
- HY-115924
-
|
|
CDK
|
Cancer
|
|
CDK1-IN-1 is a potent CDK1 inhibitor (CDK1/CycB IC50=161.2 nM) with potential antiproliferative activity and selectivity for cancer tissues. CDK1-IN-1 induces apoptosis in p53 dependent manner through the intrinsic apoptotic pathway. CDK1-IN-1 is a potential targeted antitumor agent .
|
-
- HY-181072
-
|
|
Mitochondrial Metabolism
DNA/RNA Synthesis
Oxidative Phosphorylation
|
Cancer
|
|
POLRMT-IN-4 is a photoactivated mitochondrial RNA polymerase (POLRMT) inhibitor. POLRMT-IN-4 can be liberated from the photoactivatable prodrug upon irradiation, enables spatiotemporally precise inhibition and localized tissue selectivity. POLRMT-IN-4 disrupts mitochondrial transcription, impairs oxidative phosphorylation, and suppresses cancer cell proliferation. POLRMT-IN-4 can be used in research on various cancers, such as pancreatic cancer .
|
-
- HY-D2973
-
|
|
Fluorescent Dye
|
Others
|
|
YH-APN is a high-performance APN activated near-infrared fluorescent probe. YH-APN has high sensitivity, high selectivity, fast response, and can achieve extremely high tumor/normal tissue signal-to-noise ratio through in situ spraying. YH-APN can specifically distinguish cancer cells with high expression of APN from normal cells and monitor the migration of cancer cells .
|
-
- HY-B0561
-
|
SC9420
|
Mineralocorticoid Receptor
Androgen Receptor
Autophagy
Calcium Channel
|
Cardiovascular Disease
Metabolic Disease
Endocrinology
Cancer
|
|
Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC50=24 nM) and androgen receptor (IC50=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca 2+ channels to exert antihypertensive effects .
|
-
- HY-116771
-
|
|
Adrenergic Receptor
|
Metabolic Disease
|
|
CL316243 free acid is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors. CL316243 free acid is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate. CL316243 free acid has the potential for the treatment obesity, diabetes and urge urinary incontinence .
|
-
- HY-153114
-
|
|
FXR
|
Inflammation/Immunology
|
|
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC50 values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis .
|
-
- HY-116771A
-
CL 316243
Maximum Cited Publications
24 Publications Verification
|
Adrenergic Receptor
|
Metabolic Disease
|
|
CL316243 is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors .CL316243 is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate . CL316243 has the potential for the treatment obesity, diabetes and urge urinary incontinence .
|
-
- HY-15606
-
|
NSP-989
|
Progesterone Receptor
|
Endocrinology
|
|
Tanaproget is an orally effective, selective nonsteroidal progesterone receptor (PR) agonist targeting human PR with an IC50 of 1.7 nM. Tanaproget promotes the interaction between PR receptors and coactivators (such as SRC-1), thereby inhibiting the secretion of matrix metalloproteinases (MMP-3/MMP-7) and reducing endometrial tissue invasion and angiogenesis. Tanaproget can be used for contraception and endometriosis inhibition research .
|
-
- HY-171590
-
|
|
Salt-inducible Kinase (SIK)
|
Inflammation/Immunology
|
|
SIK2-IN-3 is an orally active SIK1/2 selective inhibitor (IC50: 0.128/0.084 μM). SIK2-IN-3 inhibits CRTC3 phosphorylation and myeloid cell pro-inflammatory cytokine production. SIK2-IN-3 ameliorates systemic and tissue inflammatory responses in a mouse anti-CD40 colitis model .
|
-
- HY-185063
-
|
|
Drug Derivative
|
Inflammation/Immunology
Cancer
|
|
Budesonide 21-palmitate is a lipophilic ester prodrug of Budesonide (HY-13580), can be formulated into liposomal formulations. Budesonide 21-palmitate exhibts anti-inflammatory and anti-allergic activities. Budesonide 21-palmitate can achieve selective passive targeted delivery of drugs to tumor tissues (such as lung tumors). Budesonide 21-palmitate can be used for drug delivery in inflammatory and allergic research .
|
-
- HY-183978
-
|
|
Renin
|
Cardiovascular Disease
|
|
KRI-1314 is an orally active human renin inhibitor with selectivity for primate renin over non-primate renin. KRI-1314 competitively inhibits the binding of recombinant human renin to its substrate, reduces plasma renin activity, lowers blood pressure, and exhibits high stability in tissue homogenates. KRI-1314 is applicable to research on renin-dependent hypertension and hypertension-related studies .
|
-
- HY-101176R
-
|
|
Reference Standards
Melatonin Receptor
|
Cancer
|
|
2-Iodomelatonin (Standard) is the analytical standard of 2-Iodomelatonin. This product is intended for research and analytical applications. 2-Iodomelatonin is a potent agonist of melatonin receptor 1 (MT1) with a Ki value of 28 pM, it is more 5-fold selective for MT1 ?over MT2 . 2-iodomelatonin can be used to identify, characterize and localize melatonin binding sites in the brain and peripheral tissues .
|
-
- HY-181094
-
|
|
Glycosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-110 is a selective and orally active competitive inhibitor of α-Glucosidase with an IC50 of 7.09 μM and a Ki of 6.9 μM. α-Glucosidase-IN-110 can reduce fasting blood glucose levels, improve glucose tolerance, and restore the histomorphology of liver and pancreatic tissues in diabetic rat models. α-Glucosidase-IN-110 can be used for the research of diabetes .
|
-
- HY-116908
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
SB-272183 is a selective 5-HT1A, 5-HT1B and 5-HT1D receptor antagonist. In addition, SB-272183 is also a potent and selective ligand for 5-HT1A, 5-HT1B and 5-HT1D receptors in human recombinant and native tissues with pKi values of 8.0, 8.1 and 8.7, respectively. SB-272183 can be used in antidepressant research .
|
-
- HY-136675
-
|
|
Fluorescent Dye
|
Others
|
|
ASMI is a ratiometric, two-photon excited fluorescent probe, composed of a highly two-photon active and biocompatible merocyanine fluorophore and an acrylate moiety as a thiol reactive site. ASMI is able to selectively detect and monitor mitochondrial Cys with rapid responsiveness, imaging living cells and intact tissues with high contrast and brightness at a depth of 150 μm. The two-photon action cross section (Φσmax) of ASMI is 65.2 GM, corresponding to an excitation wavelength (λex) of 740 nm.
|
-
- HY-169179
-
|
|
PROTACs
STAT
|
Cancer
|
AK-1690 is a selective PROTAC degrader targeting STAT6 (DC50=1 nM) with a Ki of 6 nM against human STAT6. AK-1690 degrades STAT6 via the interaction of STAT6 with cereblon and a ubiquitin-like process. AK-1690 effectively depletes STAT6 protein in mouse liver and lung tissues, and is applicable to research related to leukemia, Hodgkin's lymphoma, follicular lymphoma, etc. .
|
-
- HY-P1116
-
PBP10
1 Publications Verification
|
Bacterial
Reactive Oxygen Species (ROS)
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
PBP10 is a decapeptide. PBP10 selectively binds to lipoteichoic acid (LTA), lipopolysaccharide (LPS) and phosphatidylinositol-4,5-bisphosphate (PIP2). PBP10 penetrates cell membranes and possesses bactericidal, anti-inflammatory, cell motility-inhibiting and actin assembly-regulating activities. PBP10 is applicable to relevant research on bacterial infections, microbe-induced inflammation, skin and soft tissue infections, as well as sepsis .
|
-
- HY-P5421
-
|
|
Proton Pump
|
Others
|
|
Caloxin 1B1 is a biological active peptide. (Caloxin 1b1 is obtained by screening for binding to extracellular domain 1 of PMCA4, which inhibited PMCA extracellularly, selectively, and had a higher affinity for PMCA4 than PMCA1. Because caloxin 1b1 had been selected to bind to an extracellular domain of PMCA, it could be added directly to cells and tissues to examine its effects on smooth muscle and endothelium.)
|
-
- HY-P0036D
-
|
|
Drug Derivative
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
Apoptosis
|
Cancer
|
|
NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors. .
|
-
- HY-16923
-
|
BIII-890; BIII-890 CL free acid
|
Sodium Channel
|
Neurological Disease
|
|
Crobenetine (BIII-890), a benzomorphan derivative, is a potent, selective, and highly use-dependent Na + channel blocker. Crobenetine displaces [3H]BTX from site 2 of the Na + channel (IC50=49 nM) in rat brain synaptosomes, yet exhibits only low binding affinity for other receptors and ion channels. Crobenetine protects brain tissue from the deleterious effects of focal cerebral ischemia in rodents .
|
-
- HY-182898
-
|
|
Apoptosis
Glycosidase
|
Inflammation/Immunology
|
|
Gal-dMor-Gem is a selective senescent cell scavenger, Apoptosis inducer, and a prodrug of Gemcitabine (HY-17026). Gal-dMor-Gem releases Gemcitabine upon activation by Esterases and β-gal. Gal-dMor-Gem reduces SA-β-gal, preferentially induces apoptosis in senescent cells, regulates apoptosis-related proteins, accumulates in senescent tissues, and ameliorates senescence-related organ phenotypes. Gal-dMor-Gem is applicable to research on chemotherapy-induced senescence .
|
-
- HY-150701
-
|
|
Glucocorticoid Receptor
Mineralocorticoid Receptor
11β-HSD
|
Metabolic Disease
|
|
INCB13739 is an orally active, potent, selective and tissue-specific11β-HSD1 (11β-hydroxysteroid dehydrogenase 1) inhibitor, with IC50 values of 3.2 nM (11β-HSD1 enzymatic) and 1.1 nM (11β-HSD1 PBMC), respectively. INCB13739 can be used for type 2 diabetes mellitus (T2DM) and obesity research .
|
-
- HY-10569R
-
|
ACT-128800 (Standard)
|
Reference Standards
LPL Receptor
|
Inflammation/Immunology
|
|
Ponesimod (Standard) is the analytical standard of Ponesimod. This product is intended for research and analytical applications. Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .
|
-
- HY-180883
-
|
|
Orthopoxvirus
|
Infection
|
|
ZW-2038 is a potent and selective antiviral compound against vaccinia virus (VACV), monkeypox virus (MPXV), and cowpox virus (CPXV). ZW-2038 suppresses VACV DNA replication and downstream post-replicative gene expression, albeit without inhibiting MPXV resolvase (Mpr). ZW-2038 demonstrates potent antiviral activity in complex human and animal tissue models. ZW-2038 can be used for orthopoxviruses infection research .
|
-
- HY-18572S1
-
|
|
Isotope-Labeled Compounds
Herbicide
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
2,4-D-d3 is the deuterium labeled 2,4-D (HY-18572) . 2,4-D (2,4-Dichlorophenoxyacetic acid) is a selective systemic herbicide for the control of broad-leaved weeds. 2,4-D acts as a plant hormone, causing uncontrolled growth in the meristematic tissues. 2,4-D inhibits DNA and protein synthesis and thereby prevents normal plant growth and development .
|
-
- HY-P1116A
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
PBP10 TFA is a decapeptide. PBP10 TFA selectively binds to lipoteichoic acid (LTA), lipopolysaccharide (LPS) and phosphatidylinositol-4,5-bisphosphate (PIP2). PBP10 TFA penetrates cell membranes and possesses bactericidal, anti-inflammatory, cell motility-inhibiting and actin assembly-regulating activities. PBP10 TFA is applicable to relevant research on bacterial infections, microbe-induced inflammation, skin and soft tissue infections, as well as sepsis .
|
-
- HY-B0639
-
|
WR2721
|
MDM-2/p53
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
Amifostine (WR2721) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine protects cells from damage by scavenging oxygen-derived free radicals. Amifostine reduces renal toxicity and has antiangiogenic action .
|
-
- HY-13508
-
|
|
Histamine Receptor
|
Inflammation/Immunology
|
|
JNJ-7777120 is a potent and selective histamine H4 receptor antagonist (Ki=4.5 nM). JNJ-7777120 effectively blocks histamine-induced migration of mouse tracheal mast cells from connective tissue to epithelial cells. JNJ-7777120 also significantly blocks neutrophil infiltration in a mouse Zymosan-induced peritonitis model. JNJ-7777120 has a good potential to study antipruritic and anti-inflammatory .
|
-
- HY-103195R
-
|
|
Reference Standards
Adenylate Cyclase
|
Metabolic Disease
|
|
NKY80 (Standard) is the analytical standard of NKY80 (HY-103195). This product is intended for research and analytical applications. NKY80 is a potent, selective and non-competitive adenylyl cyclase (AC) type V isoform inhibitor with IC50s of 8.3 µM, 132 µM and 1.7 mM for type V, III and II, respectively. NKY80 is a non-nucleoside quinazolinone and regulates the AC catalytic activity in heart and lung tissues .
|
-
- HY-111952
-
|
CID 16016685
|
Endogenous Metabolite
|
Others
|
|
SR-4995 (CID 16016685) is a highly effective and selective ligand for α-β-hydrolase domain-containing 5 (ABHD5), facilitating the activation of adipose triglyceride lipase (ATGL) by displacing ABHD5 from its inhibitory regulators, perilipin-1 (PLIN1) and PLIN5. It directly interacts with ABHD5, inhibiting its association with PLIN1, and promotes lipolysis in adipocytes and muscle tissues while circumventing PKA-dependent signaling pathways.
|
-
- HY-150057
-
|
|
Cannabinoid Receptor
|
Others
|
|
CB1R Allosteric modulator 4 is a positive allosteric modulator of cannabinoid type-1 (CB1R) with good biological activity. CB1R Allosteric modulator 4 inhibits cAMP production and shows robust activity in β-arrestin-2 recruitment .
|
-
- HY-P1106
-
|
|
CRFR
|
Cardiovascular Disease
|
|
K41498 is a highly selective CRF 2 receptor antagonist, with a Ki of 0.66 nM for human CRF2α receptor and a Ki of 0.62 nM for human CRF2β receptor. K41498 inhibits cAMP accumulation in cells expressing CRF2. K41498 antagonizes the hypotensive response induced by systemic administration of urocortin in conscious rats. K41498 undergoes radioiodination without loss of activity and serves for autoradiographic studies of native CRF2 receptors in rat brain and peripheral tissues .
|
-
- HY-159500A
-
|
OTL-0078 sodium; OTL78 sodium
|
Biochemical Assay Reagents
|
Cancer
|
|
Zopocianine sodium (OTL-0078 sodium; OTL78 sodium) is a near-infrared optical probe targeting PSMA. Zopocianine sodium binds to PSMA on the surface of PSMA-expressing cells, enters cells via receptor-mediated endocytosis, and accumulates in acidic endosomes. Zopocianine sodium selectively accumulates in PSMA-positive cancer tissues and enables the detection of small tumors, primary prostate tumors, and locoregional metastases. Zopocianine sodium helps achieve negative tumor surgical margins during fluorescence-guided surgery. Zopocianine sodium is applicable to research related to prostate cancer .
|
-
- HY-159500
-
|
OTL-0078; OTL78
|
PSMA
|
Cancer
|
|
Zopocianine (OTL-0078; OTL78) is a near-infrared optical probe targeting PSMA. Zopocianine binds to PSMA on the surface of PSMA-expressing cells, enters cells via receptor-mediated endocytosis, and accumulates in acidic endosomes. Zopocianine selectively accumulates in PSMA-positive cancer tissues and enables the detection of small tumors, primary prostate tumors, and locoregional metastases. Zopocianine helps achieve negative tumor surgical margins during fluorescence-guided surgery. Zopocianine is applicable to research related to prostate cancer .
|
-
- HY-138454
-
|
Mercaptoethylguanidine hemisulfate
|
NO Synthase
|
Inflammation/Immunology
|
|
MEG (Mercaptoethylguanidine) hemisulfate is a potent and selective inhibitor of the inducible NO synthase (iNOS), with EC50s of 11.5, 110, and 60 μM for iNOS, ecNOS, and bNOS respectively in tissue homogenates. MEG hemisulfate is also a potent scavenger of peroxynitrite and inhibits peroxynitrite-induced oxidative processes. MEG hemisulfate has a protective effect in many experimental models of inflammation, including ischemia/reperfusion injury, periodontitis, hemorrhagic shock, inflammatory bowel disease, and endotoxic and septic shock .
|
-
- HY-103455
-
|
|
Estrogen Receptor/ERR
|
Others
|
|
ZK164015 is an estrogen-glucocorticoid receptor chimera that can be used as a compound screening tool to evaluate tissue-selective estrogen activity. ZK164015 was used to evaluate its effects on ER function in osteoblasts in studies based on green fluorescent protein (GFP)-receptor chimeras. In osteoblast-like (ROS and U2OS) and breast cancer (MCF7) cells, ZK164015 showed different effects in response to ER agonists, including modulation of ERE-luc activity and effects on nuclear mobility.
|
-
- HY-P1821A
-
|
MHP4-14 TFA
|
PKC
|
Neurological Disease
|
|
Myelin Basic Protein (MHP4-14) TFA, a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein TFA is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .
|
-
- HY-18572S
-
|
2,4-Dichlorophenoxyacetic acid-13C6
|
Isotope-Labeled Compounds
Herbicide
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
2,4-D- 13C6 is the 13C-labeled 2,4-D (HY-18572). 2,4-D (2,4-Dichlorophenoxyacetic acid) is a selective systemic herbicide for the control of broad-leaved weeds. 2,4-D acts as a plant hormone, causing uncontrolled growth in the meristematic tissues. 2,4-D inhibits DNA and protein synthesis and thereby prevents normal plant growth and development .
|
-
- HY-W009411
-
|
|
Fluorescent Dye
|
Others
|
|
Dansyl hydrazine is a carbohydrate-specific fluorescent dye (Ex/Em = 340 nm/525 nm). Dansyl hydrazine undergoes a condensation reaction with aldehyde groups generated by periodate oxidation on carbohydrate-containing structures to form fluorescent hydrazone compounds. Dansyl hydrazine selectively stains polysaccharides in formalin-fixed, paraffin-embedded human post-mortem brain tissues, revealing detailed structural features. Dansyl hydrazine is applicable to research related to Alzheimer's disease, Lafora disease, and polyglucosan body disease .
|
-
- HY-P1821
-
|
MHP4-14
|
PKC
|
Neurological Disease
|
|
Myelin Basic Protein (MHP4-14), a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .
|
-
- HY-B0639A
-
|
WR2721 trihydrate
|
MDM-2/p53
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
Amifostine trihydrate (WR2721 trihydrate) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine trihydrate selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine trihydrate is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine trihydrate protects cells from damage by scavenging oxygen-derived free radicals. Amifostine trihydrate reduces renal toxicity and has antiangiogenic action .
|
-
- HY-118200
-
|
|
Adrenergic Receptor
|
Neurological Disease
|
BRL-41992 is a selective α₂B-adrenergic receptor antagonist. BRL-41992 exhibits 94-fold higher selectivity for the α₂B-receptor than for the α₂A-receptor with Kᵢ values in neonatal rat lung tissue (expressing the α₂B-receptor) and in human platelet membranes (expressing the α₂A-receptor) of 1.1 and 103.3 nM. BRL-41992 can be used to verify the functional differences of α₂ receptor subtypes .
|
-
- HY-10862R
-
|
Benzothiazole analog 3 (Standard)
|
Reference Standards
FAAH
Autophagy
|
Neurological Disease
Cancer
|
FAAH inhibitor 1 (Standard) is the analytical standard of FAAH inhibitor 1 (HY-10862). This product is intended for research and analytical applications. FAAH inhibitor 1 (compound 3) is a selective reversible FAAH inhibitor. FAAH inhibitor 1 has no off-target activity with respect to other serine hydrolases. FAAH inhibitor 1 is exclusively specific against FAAH in rat brain with an IC50 value of 18 nM and had no missing protein bands in all the other tissues. FAAH inhibitor 1 can be used for neurological disorders research .
|
-
- HY-13981
-
|
LGD-4033
|
Androgen Receptor
Apoptosis
Insulin Receptor
Caspase
|
Metabolic Disease
Endocrinology
|
|
Ligandrol is an orally active, selective androgen receptor (AR) agonist. Ligandrol enhances protein synthesis, inhibits muscle breakdown and oxidative stress, improves muscle cell viability and bone tissue microstructure, and reduces Cisplatin (HY-17394)-induced muscle toxicity and apoptosis. Ligandrol promotes muscle growth, protects bone structure, and has anti-diabetic, anti-apoptotic and antioxidant effects. Ligandrol can antagonize Streptozotocin (HY-13753) damage to pancreatic islets and improve the symptoms of type 2 diabetes .
|
-
- HY-D2186
-
|
|
Biochemical Assay Reagents
|
Others
|
|
BTD probe-1 is a benzothiazine-based chemoproteomic probe and selective protein S-sulfenic acid (Cys-SOH) labeling agent. BTD probe-1 labels protein S-sulfenic acids in vitro in cell and tissue samples, and in situ in intact cells, enabling detection or enrichment of modified proteins/peptides. BTD probe-1 exhibits no cytotoxicity in cells at concentrations ≤1 mM. BTD probe-1 enables global, site-specific mapping and quantification of cysteine S-sulfenylation in complex proteomes with lower input material .
|
-
- HY-P1106A
-
|
|
CFTR
|
Cardiovascular Disease
|
|
K41498 TFA is a highly selective CRF 2 receptor antagonist, with a Ki of 0.66 nM for human CRF2α receptor and a Ki of 0.62 nM for human CRF2β receptor. K41498 TFA inhibits cAMP accumulation in cells expressing CRF2. K41498 TFA antagonizes the hypotensive response induced by systemic administration of urocortin in conscious rats. K41498 TFA undergoes radioiodination without loss of activity and serves for autoradiographic studies of native CRF2 receptors in rat brain and peripheral tissues .
|
-
- HY-10656R
-
|
|
Reference Standards
Urotensin Receptor
|
Inflammation/Immunology
|
|
SB-657510 (Standard) is the analytical standard of SB-657510 (HY-10656). This product is intended for research and analytical applications. SB-657510 is a selective urotensin II (UII) receptor (UT) antagonist. The Ki values are 61, 17, 30, 65 and 56 nM for human, monkey, cat, rat and mouse receptors, respectively. SB-657510 exerts anti-inflammatory effects by inhibiting UII-induced upregulation of inflammatory mediators such as adhesion molecules, cytokines, and tissue factor in human vascular endothelial cells .
|
-
- HY-14759
-
|
PAZ-417
|
PAI-1
Amyloid-β
|
Neurological Disease
|
|
Aleplastinin (PAZ-417) is an orally active, blood-brain barrier permeable, selective SERPINE1 (PAI-1) inhibitor (IC50=655 nM). Aleplastinin activates the tissue type plasminogen activator (tPA)/fibrinolysis cascade by inhibiting PAI-1, thereby promoting the degradation of amyloid-β (Aβ) oligomers and monomers. Aleplastinin can significantly reduce plasma and brain Aβ levels, improve memory impairment, and reverse cognitive impairment. Aleplastinin can be used for research on Alzheimer's disease .
|
-
- HY-12093
-
MMP408
1 Publications Verification
|
MMP
|
Inflammation/Immunology
|
|
MMP408 is a selective and orally effective inhibitor of MMP-12 with IC50 values for human, mouse and rat MMP-12 of 2 nM, 160 nM and 3 μM respectively. MMP408 exhibits IC50 value for human MMP-13 of 120 nM, and its activity against other MMPs is weak. MMP408 can alleviate inflammation, fibrosis and tissue remodeling by inhibiting MMP-12. MMP408 can be used in the research of chronic obstructive pulmonary disease and chronic sinusitis with nasal polyps .
|
-
- HY-16936
-
|
|
LRRK2
|
Neurological Disease
|
|
JH-II-127 is an orally active, highly potent, selective and brain-permeable LRRK2 inhibitor, with IC50s of 6, 2 and 48 nM for wild-type LRRK2 and LRRK2-G2019S and mutant LRRK2-A2016T. JH-II-127 inhibits Ser935 phosphorylation in all tissues of mice, including the brain. JH-II-127 can be used in the study of parkinson's syndrome .
|
-
- HY-10569S
-
|
ACT-128800-d4
|
Isotope-Labeled Compounds
LPL Receptor
|
Others
|
|
Ponesimod-d4 (ACT-128800-d4) is the deuterium labeled Ponesimod (HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .
|
-
- HY-D0163
-
|
|
DNA Stain
|
Others
|
|
Methyl Green is a non-intercalating fluorescent labeling agent that selectively binds to the major groove of DNA. Methyl Green electrostatically interacts with the major groove of DNA through positively charged groups, exhibiting key activities such as high affinity, resistance to photobleaching, and stable fluorescence emission. Methyl Green can be directly measured by microscopy and flow cytometry, with peaks at 633 and 677 nm. Methyl Green can be used for fluorescent labeling of the nuclei of embryonic tissues or cells, or DNA staining and cell activity detection in gel electrophoresis[1][2][3].
|
-
- HY-18572S2
-
|
|
Isotope-Labeled Compounds
Herbicide
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
2,4-D-d5 (2,4-Dichlorophenoxyacetic acid-d5) is the deuterium labeled 2,4-D (HY-18572) . 2,4-D (2,4-Dichlorophenoxyacetic acid) is a selective systemic herbicide for the control of broad-leaved weeds. 2,4-D acts as a plant hormone, causing uncontrolled growth in the meristematic tissues. 2,4-D inhibits DNA and protein synthesis and thereby prevents normal plant growth and development .
|
-
- HY-123659
-
|
|
Na+/H+ Exchanger (NHE)
Apoptosis
|
Cardiovascular Disease
Cancer
|
|
KR-33028 is a selective NHE1 inhibitor. KR-33028 reduces hypoxia-induced necrosis and apoptosis in H9c2 cells. KR-33028 inhibits hypoxia-induced increases in cytoplasmic and mitochondrial Ca 2+ levels and cytochrome c release. KR-33028 improves cardiac contractility, reduces lactate dehydrogenase release, and increases tissue ATP, creatine phosphate, and glycogen levels. KR-33028 can be used in research on cancers such as cardioblastoma and cardiovascular diseases such as ischemic stroke .
|
-
- HY-145801
-
XT2
2 Publications Verification
|
NF-κB
|
Inflammation/Immunology
|
|
XT2 is a potent, orally active, and selective inhibitor of NF-κB-inducing kinase (NIK) with an IC50 of 9.1 nM. XT2 suppresses CCl4-induced upregulation of ALT, a key biomarker of acute liver injury. XT2 also decreases immune cell infiltration into the injured liver tissue. XT2 has the potential for the research of liver inflammatory diseases . XT2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-172905
-
|
|
Others
|
Cardiovascular Disease
|
|
BCX-3607 is an orally active tissue factor/factor VIIa (TF-FVIIa) inhibitor (IC50: 4 nM). BCX-3607 blocks the extrinsic coagulation pathway by inhibiting the TF-FVIIa complex and significantly prolongs the prothrombin time (PT). BCX-3607 has a higher selectivity for TF-FVIIa than other serine proteases (such as thrombin, FXa, etc.). BCX-3607 can reduce thrombus weight and inflammatory response, and has both anti-thrombotic and anti-inflammatory effects. BCX-3607 can be used in the study of thrombosis-related diseases .
|
-
- HY-13508R
-
|
|
Histamine Receptor
|
Inflammation/Immunology
|
|
JNJ-7777120 (Standard) is the analytical standard of JNJ-7777120. This product is intended for research and analytical applications. JNJ-7777120 is a potent and selective histamine H4 receptor antagonist (Ki=4.5 nM). JNJ-7777120 effectively blocks histamine-induced migration of mouse tracheal mast cells from connective tissue to epithelial cells. JNJ-7777120 also significantly blocks neutrophil infiltration in a mouse Zymosan-induced peritonitis model. JNJ-7777120 has a good potential to study antipruritic and anti-inflammatory .
|
-
- HY-W338446
-
|
|
Tau Protein
|
Neurological Disease
|
|
BF-170 is a selective tau fibril binding agent with an EC50 of 221 nM. It exhibits good blood-brain barrier permeability, and after intravenous injection in mice, the concentration in brain tissue reaches 9.1% ID/g within 2 minutes (with a brain clearance rate of 0.25% ID/g after 30 minutes). BF-170 can be used as a probe for tau protein pathology imaging in Alzheimer's disease (AD). It plays an important role in early-stage AD research and holds potential for imaging studies of tau-related neurodegenerative diseases .
|
-
- HY-P11618
-
|
|
Glycoprotein VI
|
Cancer
|
|
10P3Me is a Glypican-3 (GPC3)-targeting probe with a Ka of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for PET imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions .
|
-
- HY-P10420
-
|
|
CD47
Interleukin Related
|
Cancer
|
|
RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape .
|
-
- HY-P10709
-
|
|
Collagen
|
Cardiovascular Disease
Cancer
|
|
CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects .
|
-
- HY-183179
-
|
|
Adrenergic Receptor
|
Endocrinology
|
|
α1A Adrenoceptor antagonist-1 is a selective α1A adrenoceptor antagonist with a human Ki <20 nM. α1A Adrenoceptor antagonist-1 exhibits activity against benign prostatic hyperplasia (BPH) to enable less hindered urine flow. α1A Adrenoceptor antagonist-1 relaxes α1a receptor-enriched urethral smooth muscle tissue without inducing hypotension. α1A Adrenoceptor antagonist-1 can be used for the research of benign prostatic hyperplasia (BPH) .
|
-
- HY-125961
-
|
|
FGFR
Glycosyltransferase
|
Cancer
|
|
T3Inh-1 is a potent and selective inhibitor of ppGalNAc-T3 (IC50=7 μM). T3Inh-1 reduces FGF23 hormone levels in both tissue cells and mice, without causing any toxic side effects. T3Inh-1 also prevents breast cancer cells. The enzyme ppGalNAc-T3 is implicated in at least two medically important pathways: cancer metastasis and stabilization of FGF23 (regulates phosphate levels in the bloodstream) .
|
-
- HY-158821A
-
|
|
TGF-beta/Smad
|
Neurological Disease
|
|
ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases .
|
-
- HY-162902
-
|
|
TGF-β Receptor
|
Cardiovascular Disease
|
|
ALK5-IN-82 is a potent and selective inhibitor against activin receptor-like kinase 5 (ALK5) with an IC50 value of 9.1 nM. ALK5-IN-82 inhibits the protein expression of α-smooth muscle actin (α-SMA), collagen I and tissue inhibitor of metalloproteinase 1 (TIMP-1)/matrix metalloproteinase 13 (MMP-13) in transforming growth factor-β-induced human umbilical vein endothelial cells. ALK5-IN-82 is promising for research of cardiac fibrosis .
|
-
- HY-P99575
-
|
AMG-757
|
Notch
|
Inflammation/Immunology
Cancer
|
|
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
|
-
- HY-W009411S
-
|
|
Isotope-Labeled Compounds
Fluorescent Dye
|
Others
|
|
Dansyl hydrazine- 13C2 is the 13C-labeled Dansyl hydrazine (HY-W009411). Dansyl hydrazine is a carbohydrate-specific fluorescent dye (Ex/Em = 340 nm/525 nm). Dansyl hydrazine undergoes a condensation reaction with aldehyde groups generated by periodate oxidation on carbohydrate-containing structures to form fluorescent hydrazone compounds. Dansyl hydrazine selectively stains polysaccharides in formalin-fixed, paraffin-embedded human post-mortem brain tissues, revealing detailed structural features. Dansyl hydrazine is applicable to research related to Alzheimer's disease, Lafora disease, and polyglucosan body disease.
|
-
- HY-10569S1
-
|
ACT-128800-d7
|
Isotope-Labeled Compounds
|
Others
|
|
Ponesimod-d7 (ACT-128800-d7) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d7 (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod-d7 activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod-d7 can protect against lymphocyte-mediated tissue inflammation .
|
-
- HY-158821
-
|
|
TGF-beta/Smad
|
Neurological Disease
|
|
ISTH0036 is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases .
|
-
- HY-180306
-
|
|
Estrogen Receptor/ERR
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
Fluoroestradiol is an Estrogen receptor PET imaging tracer precursor. Fluoroestradiol, when radiolabeled with 18F, can be used as an Estrogen receptor PET imaging tracer. 18F-Fluoroestradiol exhibits the highest uptake selectivity and target-to-background ratio among
several 18F-labeled estrogens. 18F-Fluoroestradiol has demonstrated Estrogen receptor expression in normal brain tissues and in meningiomas. 18F-Fluoroestradiol can quantify regional Estrogen receptor expression in breast cancer. 18F-Fluoroestradiol has potential applications in assessing and monitoring heterogeneity in ovarian cancer .
|
-
- HY-114332
-
|
|
MAP3K
JNK
|
Neurological Disease
Metabolic Disease
|
|
GNE-8505 is an orally active, blood-brain barrier-permeable selective dual leucine zipper kinase (DLK) inhibitor. GNE-8505 has an IC50 of 0.144 μM for pJNK, and EC50 of 0.457 μM for DRG. GNE-8505 inhibits the DLK/JNK pathway, reduces stress-induced c-Jun phosphorylation levels, decreases neuronal death and suppresses axonal degeneration. GNE-8505 reduces phosphorylated c-Jun levels in the retina, spinal cord and brain tissues of mice. GNE-8505 is applicable to research related to Alzheimer's disease and amyotrophic lateral sclerosis (ALS) .
|
-
- HY-Y1147
-
|
Maleic acid diethyl ester
|
Biochemical Assay Reagents
|
Others
|
|
Diethyl maleate (DEM) is an orally available, effective glutathione (GSH) depletor that crosses the blood-brain barrier. Diethyl maleate covalently binds irreversibly to GSH via glutathione S-transferase with an in vitro IC50 of 0.1-0.5 mM. Diethyl maleate selectively depletes GSH in liver, lung, and brain tissues, exacerbating oxidative stress and enhancing hyperbaric oxygen toxicity. Diethyl maleate promotes precursor amino acid uptake and in turn promotes GSH synthesis by upregulating the activity of the cystine-glutamate transporter XO -. Diethyl maleate can be used to study redox homeostasis and GSH protection mechanisms in oxidative stress-related diseases such as hyperbaric oxygen injury and metabolic diseases[1][2][3].
|
-
- HY-100113
-
|
AT2 receptor agonist C21
|
Angiotensin Receptor
p38 MAPK
TGF-beta/Smad
TGF-β Receptor
MMP
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Buloxibutid (AT2 receptor agonist C21) is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a Ki value of 0.4 nM for porcine AT2R. Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase MMP-13) and tissue repair mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis .
|
-
- HY-100113A
-
|
AT2 receptor agonist C21 hydrochloride
|
Angiotensin Receptor
p38 MAPK
TGF-β Receptor
TGF-beta/Smad
MMP
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Buloxibutid (AT2 receptor agonist C21) hydrochloride is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a Ki value of 0.4 nM for porcine AT2R. Buloxibutid hydrochloride exerts vasodilatory, anti-inflammatory, antifibrotic (promoting the expression of collagenase MMP-13) and tissue repair effects mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway and inflammatory NF-κB pathway. Buloxibutid hydrochloride can be used in research related to idiopathic pulmonary fibrosis, hypertension, systemic sclerosis and other conditions .
|
-
- HY-D3179
-
|
|
Fluorescent Dye
BCRP
|
Neurological Disease
|
|
CDg13 is a fluorescent probe that specifically detects living neural stem/progenitor cells. CDg13 localizes to the endoplasmic reticulum via its dihexyl moiety, with no interaction with endoplasmic reticulum biomolecules. CDg13 undergoes selective efflux by active ABCG2 transporters, with increased intracellular accumulation following ABCG2 inhibition or knockdown. CDg13 isolates and enriches self-renewable neural stem/progenitor cells from embryonic mouse brain tissue, stains neural stem/progenitor cells brightly, and sorts ABCG2low cell populations from heterogeneous populations . (Ex/Em = 520/553 nm)
|
-
- HY-W205529
-
|
|
Fluorescent Dye
|
Neurological Disease
|
|
RO 16-6491 Free base is a selective, reversible inhibitor of monoamine oxidase type B (MAO-B), exhibiting high affinity and specificity for binding sites in human frontal cortex mitochondria and platelet membranes. RO 16-6491 demonstrates a fast dissociation of bound radioactivity at 20 degrees C, indicating its dynamic binding properties. RO 16-6491 also acts as a substrate for MAO-B, suggesting that its oxidation may produce a stable intermediate responsible for its potent inhibitory effects. RO 16-6491 serves as an excellent radioligand probe for investigating the regional tissue distribution of MAO-B in various physiological and pathological states.
|
-
- HY-161449
-
|
|
11β-HSD
|
Metabolic Disease
|
|
JTT-654 is an orally active, potent and selective11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor. The IC50 of JTT-654 for 11β-HSD1 is 4.65, 0.97, and 0.74 nM in human, rat, and mouse recombinant enzymes, respectively. JTT-654 showed competitive inhibition against human recombinant enzyme. The IC50 value for human 11β-HSD2 is > 30 μM (human 11β-HSD2 is responsible for the reverse reaction against human 11β-HSD1). JTT-654 ameliorates insulin resistance and non-obese type 2 diabetes by inhibiting adipose tissue and liver 11β-HSD1 .
|
-
- HY-117991
-
|
|
VEGFR
|
Cancer
|
|
DW10075 is a highly selective and orally active VEGFR inhibitor targeting the VEGF/VEGFR pathway. DW10075 selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3, but has no effect on FGFR and PDGFR. DW10075 inhibits VEGF-induced HUVEC proliferation, migration, and tube formation. And DW10075 inhibits angiogenesis in both the rat aortic ring model and the chick chorionic membrane model. DW10075 also exhibits antiproliferative activity against human cancer cell lines, with IC50s of 2.2 μM and 22.2 μM against U87-MG human glioblastoma cells and A375 melanoma cells, respectively. In the nude mouse U87-MG xenograft tumor model, DW10075 (po) significantly inhibits tumor growth and reduces the expression of CD31 and Ki67 in tumor tissues.
|
-
- HY-N2909
-
|
|
NF-κB
RIP kinase
Mixed Lineage Kinase
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .
|
-
- HY-P3849
-
|
LMN-NKA
|
Neurokinin Receptor
|
Neurological Disease
|
|
[Lys5,MeLeu9,Nle10]Neurokinin A(4-10) (LMN-NKA), an analogue of Neurokinin A, is a selective and potent NK2R agonist. [Lys5,MeLeu9,Nle10]Neurokinin A(4-10) has prokinetic activity. [Lys5,MeLeu9,Nle10]Neurokinin A(4-10) can be used to study the roles of the NK-2 receptor in smooth muscle contraction in numerous tissues .
|
-
![[Lys5,MeLeu9,Nle10]Neurokinin A(4-10)](//file.medchemexpress.com/product_pic/hy-p3849.gif)
- HY-116330
-
|
|
Calcium Channel
TRP Channel
|
Neurological Disease
Inflammation/Immunology
|
|
Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca 2+ levels by activating Ca 2+-conducting non-selective canonical TRPC6 channels and triggers adipose tissue thermogenesis via the Dlat-AMPK signaling axis to suppress obesity. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .
|
-
- HY-108596
-
|
|
Potassium Channel
|
Inflammation/Immunology
|
|
BL-1249 is a nonsteroidal anti-inflammatory agent (NSAID) and a potassium channel activator. BL-1249 potently activates K2P2.1 (TREK-1) and K2P10.1 (TREK-2) with EC50 values of 5.5 μM and 8.0 μM, respectively. BL-1249 extracellular application activates all TREK subfamily members but has no effect on other K2P subfamilies. BL-1249 exhibits more selective for the bladder (EC50 of 1.26 μM) than vascular tissue (EC50 of 21.0 μM) .
|
-
- HY-W087830
-
|
L-BPA
|
Biochemical Assay Reagents
|
Cancer
|
|
L-p-Boronophenylalanine is a boron-containing substrate for L-type amino acid transporters (LAT1 and LAT2). L-p-Boronophenylalanine enters tumor cells by competing with natural amino acids for LAT, selectively accumulating boron in cancer cells. L-p-Boronophenylalanine can be used in boron neutron capture therapy (BNCT). When boron-10 captures thermal neutrons, a nuclear reaction occurs, producing high-energy alpha particles and lithium nuclei, which kill cancer cells at close range with little damage to surrounding tissues. L-p-Boronophenylalanine can be used in cancer research, especially glioblastoma and anaplastic astrocytoma .
|
-
- HY-158821B
-
|
|
TGF-beta/Smad
|
Neurological Disease
|
|
ISTH0036 sodium scrambled negative control is the sequence scrambled negative control of ISTH0036 sodium (HY-158821A). ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases.
|
-
- HY-103322
-
|
|
PKA
Potassium Channel
|
Metabolic Disease
Cancer
|
|
6-Bnz-cAMP sodium, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K + channel. 6-Bnz-cAMP sodium does not activate the Epac signaling pathway. It inhibits the bTREK-1 K + channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP sodium activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. It can be used in studies related to bone tissue repair and regeneration .
|
-
- HY-136831
-
|
QMPB
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
SR2640 is a highly efficient and selective LTD4/LTE4 antagonist that can specifically inhibit the smooth muscle contractions induced by LTD4 in the guinea pig ileum and trachea in a concentration-dependent manner, without affecting the contractions caused by histamine. SR2640 can concentration-dependently prevent the binding of 0.4 nM [3H] LTD4 to membrane receptors in guinea pig lung tissue, with an IC50 of 23 nM. SR2640 can shift the dose-response curve for bronchoconstriction induced by intravenous LTD4 in guinea pigs to the right, and the extent of this shift is positively correlated with the dose of SR2640 administered. SR2640 can be used in asthma research .
|
-
- HY-P991950
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
SHR-1906 is a selective fully humanized monoclonal IgG1 inhibitory antibody targeting CTGF. SHR-1906 specifically binds to CTGF, thereby blocking the interaction between CTGF and TGF-B1 with an inhibition rate of 55%. SHR-1906increases the survival rate in a pulmonary fibrosis model by reducing TGF-β1 levels and inhibiting fibrotic lesions in lung tissue in Bleomycin (HY-108345)-induced pulmonary fibrosis.SHR-1906 can be used for pulmonary fibrosis (IPF) research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-158821D
-
|
|
Fluorescent Dye
TGF-beta/Smad
|
Neurological Disease
|
|
Cy3 labled ISTH0036 sodium is a Cy3 labled ISTH0036 sodium (HY-158821A). ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases.
|
-
- HY-158821C
-
|
|
Fluorescent Dye
TGF-beta/Smad
|
Neurological Disease
|
|
FAM labled ISTH0036 sodiumis a FAM labled ISTH0036 sodium (HY-158821A). ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases.
|
-
- HY-N3945
-
|
O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396
|
Phosphodiesterase (PDE)
Calcium Channel
MMP
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Glaucine (O,O-Dimethylisoboldine) is an alkaloid extracted from Glaucium flavum that possesses various activities, including cough relief, bronchodilation, anti-inflammatory effects, analgesia, antipyretic properties, and anticancer effects. Glaucine acts as a selective and orally active inhibitor of phosphodiesterase 4 (PDE4), with a Ki of 3.4 µM in human bronchial tissues and polymorphonuclear leukocytes. Glaucine induces relaxation of human isolated bronchi by antagonizing calcium channels. Additionally, Glaucine inhibits the activation of NF-κB, leading to a reduction in the expression of the MMP-9 gene, thereby suppressing the migration and invasion of breast cancer cells. Therefore, Glaucine holds potential for research in asthma and breast cancer .
|
-
- HY-182472
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
AL-38022A is a potent and selective 5-HT2 receptor agonist (Ki ≤2.2 nM), but a significantly lower (>100-fold less) affinity for other 5-HT receptors. AL-38022A potently stimulates functional responses via 5-HT2 receptor subtypes including [Ca 2+]i mobilization and tissue contractions with apparently similar potencies and intrinsic activities. AL-38022A fully generalizes to the (±)-1-(2,5-dimethoxy 4-methylphenyl)-2-aminopropane hydrochloride (DOM) stimulus in drug discrimination paradigms. AL-38022A can be used for the glaucoma research .
|
-
- HY-181646
-
|
|
Phosphodiesterase (PDE)
TNF Receptor
|
Inflammation/Immunology
|
|
PDE4-IN-34 is a phosphodiesterase 4 (PDE4) inhibitor, with IC50 values of 19 pM and 14 pM against PDE4B1 and PDE4D2, respectively. PDE4-IN-34 shows weak inhibitory activity against PDE8A1, with an IC50 value of 4.092 μM, and exhibits significant selectivity over other subtypes (IC50 > 10 μM). PDE4-IN-34 improves pulmonary function, reduces inflammatory responses and alleviates lung tissue damage in a rat model induced by cigarette smoke combined with LPS (HY-D1056). PDE4-IN-34 can be used for research related to chronic obstructive pulmonary disease .
|
-
- HY-W116336D
-
|
|
Biochemical Assay Reagents
Fungal
Bacterial
|
Infection
Cancer
|
|
Zinc oxide, <100 nm particle size is a nitrate reductase modulator and growth promoter with plant stress resistance activity and oral toxicity. Zinc oxide, <100 nm particle size acts as a nutrient source for maize plants. By enhancing nitrate reductase activity and reducing free proline levels, it significantly improves plant height, root length and dry matter weight of maize, and its growth-promoting effect is comparable to that of traditional zinc sulfate fertilizer. Zinc oxide, <100 nm particle size induces anemia-related and persistent tissue inflammatory damage, leading to obvious histopathological adverse reactions in the stomach, pancreas, eyes and prostate of rats. Zinc oxide, <100 nm particle size acts as a non-toxic antibacterial agent and selective cytotoxin against multiple bacteria, fungi and spores .
|
-
- HY-100113R
-
|
AT2 receptor agonist C21 (Standard)
|
Angiotensin Receptor
Reference Standards
p38 MAPK
TGF-beta/Smad
TGF-β Receptor
MMP
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
Buloxibutid (AT2 receptor agonist C21) (Standard) is the analytical standard of Buloxibutid (HY-100113). This product is intended for research and analytical applications. Buloxibutid is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a Ki value of 0.4 nM for porcine AT2R. Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase MMP-13) and tissue repair mainly by activating the NO/cGMP pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis.
|
-
- HY-159771
-
|
|
FAP
|
Cancer
|
|
FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
|
-
- HY-137381
-
|
N6-Benzoyl-cAMP
|
PKA
Potassium Channel
|
Metabolic Disease
|
|
6-Bnz-cAMP, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K + channel. 6-Bnz-cAMP does not activate the Epac signaling pathway. 6-Bnz-cAMP inhibits the bTREK-1 K + channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. 6-Bnz-cAMP can be used in studies related to bone tissue repair and regeneration .
|
-
- HY-D3190
-
|
|
Fluorescent Dye
Apoptosis
|
Inflammation/Immunology
|
|
BODIPY-DOX is a conjugate composed of BODIPY and Doxorubicin (HY-15142A), as well as a pH-activated fluorescent probe for M1 macrophages and an apoptosis inducer. BODIPY-DOX undergoes pH-induced hydrazone bond cleavage in acidic M1 macrophage phagosomes, thereby releasing cytotoxic Doxorubicin (Dox) and inhibiting the function of pro-inflammatory M1 macrophages. BODIPY-DOX highly selectively inhibits the production of relevant pro-inflammatory cytokines by mouse and human monocyte-derived M1 macrophages, while exerting minimal effects on M2 or unactivated macrophages. Therefore, BODIPY-DOX enables simultaneous fluorescent tracing, differentiation and elimination of specific macrophage subsets, and exhibits the potential to regulate tissue regeneration in zebrafish models .
|
-
- HY-182503
-
|
|
Adenosine Kinase
|
Others
Inflammation/Immunology
|
|
GP515 is a potent and selective adenosine kinase inhibitor with a human IC50 of 4 nM. GP515 exerts tissue protective effects, produces long-lasting hepatic microcirculation effects after hemorrhagic shock, and induces dose- and time-related VEGF mRNA and protein expression in normoxic rat myocardial myoblasts, with additive VEGF increases during mild hypoxia and no effect during severe hypoxia. GP515 suppresses IFNγ synthesis and CD69 expression in DSS-induced colitis. GP515 also shows a dose-dependent suppression of TNF-α production with an IC50 of 80 μM and can be reversed in the presence of the cAMP antagonist (Rp)-cAMPS. Combinations of GP515 with either adenosine or rolipram led to an additive inhibition of TNF-α synthesis. GP515 can be used for the research of hemorrhagic shock .
|
-
- HY-P4744
-
|
|
Formyl Peptide Receptor (FPR)
Bacterial
|
Infection
Cancer
|
|
LL-37 amide is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED99=8.5-8.7 μg/mL). LL-37 amide exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .
|
-
- HY-120006A
-
|
|
ERK
|
Cardiovascular Disease
|
|
(rel)-AR234960 is a selective and competitive agonist of the G protein-coupled receptor MAS. (rel)-AR234960 binds to the MAS receptor to activate the downstream ERK1/2 signaling pathway, inducing the expression of connective tissue growth factor (CTGF) and its downstream collagen subtype genes (such as COL1A1, COL3A1). (rel)-AR234960 promotes collagen synthesis in cardiac fibroblasts through the MAS-ERK1/2-CTGF pathway and aggravates extracellular matrix remodeling. (rel)-AR234960's in vitro effect can be blocked by the MAS inverse agonist AR244555 and MEK1 inhibitor. (rel)-AR234960 regulates the expression of cardiac fibrosis-related genes and can be used in the study of heart failure .
|
-
- HY-108596R
-
|
|
Reference Standards
Potassium Channel
|
Inflammation/Immunology
|
|
BL-1249 (Standard) is the analytical standard of BL-1249 (HY-108596). This product is intended for research and analytical applications. BL-1249 is a nonsteroidal anti-inflammatory agent (NSAID) and a potassium channel activator. BL-1249 potently activates K2P2.1 (TREK-1) and K2P10.1 (TREK-2) with EC50 values of 5.5 μM and 8.0 μM, respectively. BL-1249 extracellular application activates all TREK subfamily members but has no effect on other K2P subfamilies. BL-1249 exhibits more selective for the bladder (EC50 of 1.26 μM) than vascular tissue (EC50 of 21.0 μM) .
|
-
- HY-P990301
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is a mouse-derived IgG2b λ type antibody inhibitor, targeting to Amyloid-beta. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) recognizes unaggregated, oligomeric or fibrillar forms of Aβ42 and unaggregated Aβ40. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is selective for human Aβ42 over Aβ40, but not amyloid precursor protein (APP). Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can immunostain human or rat and mouse tissue. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can be used for detections of western blot, immunohistochemistry, immunofluorescence, immunoprecipitation and ELISA .
|
-
- HY-P5640
-
|
|
Bacterial
Parasite
|
Infection
|
|
Tritrpticin is a porcine-derived antimicrobial peptide with properties such as membrane disruption and hemolysis. Tritrpticin disrupts the cell membranes of bacteria, fungi and Jurkat T cell leukemia cells and induces their death. Tritrpticin also enhances the efficacy of Metronidazole (HY-B0318) against *Trichomonas vaginalis*, reduces plasma endotoxin and inflammatory cytokine levels, restricts bacterial growth in blood and visceral tissues, decreases the mortality rate of septic shock in rats and enhances the therapeutic effect of ertapenem. Tritrpticin exhibits selective cytotoxicity against Jurkat T cell leukemia cells, while showing low toxicity to normal peripheral blood mononuclear cells and red blood cells, and can serve as a template for antimicrobial peptide design. Tritrpticin can be applied to research related to bacterial infections, fungal infections, trichomoniasis, septic shock and leukemia .
|
-
- HY-P4744A
-
|
|
Formyl Peptide Receptor (FPR)
Bacterial
|
Infection
Cancer
|
|
LL-37 amide TFA is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED99=8.5-8.7 μg/mL). LL-37 amide TFA exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide TFA possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .
|
-
- HY-P1130
-
|
Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
M871 (Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide) is an orally active and selective galanin receptor type 2 (GalR2) antagonist. M871 exhibits Ki values of 13.1 nM, 420 nM and >10 μM for GalR2, GalR1 and GalR3 respectively. M871 relieves the mice allergic rhinitis by reducing IgE production, as well as the number of B cells in tissues. M871 can inhibit the nerve invasion of salivary adenoid cystic carcinoma (SACC) and alleviate myocardial ischemia-reperfusion injury. M871 can be used for research on GalR2-related diseases (such as epilepsy, pain) .
|
-
- HY-178958
-
|
|
PPAR
Adenosine Receptor
Fatty Acid Synthase (FASN)
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
|
PPAR agonist 7 is an orally active pan-PPAR agonist, demonstrating potent activation of all three subtypes, PPARα (EC50 = 1.51 μM), PPARδ (EC50 = 1.11 μM), and PPARγ (EC50 = 3.14 μM). PPAR agonist 7 significantly enhances glucose uptake in adipocytes while exhibiting minimal adipogenic activity. PPAR agonist 7 can suppress PPARγ Ser273 phosphorylation in white adipose tissue and upregulate insulin-sensitizing genes. PPAR agonist 7 does not cause weight gain or fluid retention in high-fat diet (HFD)/
Streptozotocin (HY-13753) (STZ)-induced type 2 diabetes mellitus (T2DM) models. PPAR agonist 7 has selective modulation of PPAR signaling pathways without activation of adipogenic gene programs. PPAR agonist 7 can be used for the study of diabetes .
|
-
- HY-W068119A
-
|
2-Maleimidoethylamine hydrochloride
|
Biochemical Assay Reagents
|
Cancer
|
|
N-(2-Aminoethyl)maleimide (2-Maleimidoethylamine) hydrochloride is a selective covalent binding agent for thiol groups (RSGs), covalently binding to thiols via an irreversible thioether bond to prepare MMP-2-sensitive nanosystems. Under near-neutral conditions, the maleimide group in N-(2-Aminoethyl)maleimide hydrochloride binds to thiol groups via a nucleophilic addition reaction, and can be used to modify polymers or biological interfaces, enhancing mucosal adhesion and regulating the surface charge of biological interfaces. N-(2-Aminoethyl)maleimide hydrochloride can optimize the adhesion performance of drug delivery carriers and cell interactions with biological interfaces, and is applied in transmucosal drug delivery systems (such as drug carriers for oral and bladder sites) and biomaterial surface engineering research, providing support for tissue implantation, regeneration, and related drug delivery .
|
-
- HY-149662
-
|
|
Calcium Channel
ATP Synthase
Myosin
|
Cardiovascular Disease
|
|
TMDJ-035 is a high-affinity, selective RyR2 inhibitor with an EC50 of 0.0130 μM. TMDJ-035 reduces RyR2 protein expression without affecting action potential-induced Ca 2+ transients. TMDJ-035 decreases ATP content and intracellular Ca 2+ levels. TMDJ-035 inhibits arrhythmias in a CPVT mouse model carrying mutant RyR2s. TMDJ-035 has no effect on electrocardiogram parameters or cardiac systolic function. TMDJ-035 exacerbates heart failure in mouse myocardial infarction models and hypoxic cardiomyocytes by altering cardiac function, causing tissue damage, promoting inflammatory infiltration, collagen deposition, and changes in Myosin heavy chain/actin expression. TMDJ-035 can be used in studies related to heart failure, catecholaminergic polymorphic ventricular tachycardia, and arrhythmias .
|
-
- HY-145425
-
|
|
IRE1
Apoptosis
FGFR
|
Inflammation/Immunology
|
|
PAIR2 is a highly selective inhibitor targeting the kinase domain of human IRE1α, with a Ki value of 8.8 nM against human IRE1α. PAIR2 fully occupies the ATP-binding site of the IRE1α kinase domain, partially antagonizes the ribonuclease activity of IRE1α, specifically inhibits regulated IRE1α-dependent decay (RIDD) and its mediated substrate cleavage, while preserving the splicing function of Xbp1 mRNA. PAIR2 also promotes the differentiation of B cells into plasma cells, blocks IRE1α-induced cell apoptosis, and restores the expression of Fgfr2 mRNA in AT2 cells. PAIR2 effectively reaches a steady-state concentration in the lung tissues of Mus musculus, and serves as an important tool for investigating the function of the IRE1α signaling pathway in diseases such as pulmonary fibrosis .
|
-
- HY-181088
-
|
|
Phosphodiesterase (PDE)
Interleukin Related
|
Metabolic Disease
|
|
PDE3/4-IN-4 is an orally active PDE3A and PDE4B inhibitor with IC50 values of 10 nM and 9.4 nM, respectively. PDE3/4-IN-4 shows selective activity relative to most other PDE family members. PDE3/4-IN-4 modulates the cAMP/PKA/CREB signaling pathway. PDE3/4-IN-4 inhibits pro-inflammatory factor IL-6. PDE3/4-IN-4 reduces expression of inflammatory markers in liver tissue. PDE3/4-IN-4 attenuates liver fibrosis. PDE3/4-IN-4 limits liver damage in cholestatic and sepsis-induced liver disease mice models. PDE3/4-IN-4 can be used for the research of liver injury, cholestatic liver diseases, sepsis-induced liver injury .
|
-
- HY-153552A
-
|
|
FAP
|
Cancer
|
|
NH2-UAMC1110 TFA is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 TFA is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose effect, and has been used in tumor diagnosis. NH2-UAMC1110 TFA structurally incorporates an active amino group, allowing it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.) to synthesize molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 TFA specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling-related processes. Its key activity is high targeting and high affinity, and its core function is to act as a targeting module coupled with bifunctional chelators (such as DOTA, DATA5m). NH2-UAMC1110 TFA can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .
|
-
- HY-153552
-
|
|
FAP
|
Cancer
|
|
NH2-UAMC1110 is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose-response, and has been used for tumor diagnosis. NH2-UAMC1110 introduces an active amino group into its structure, enabling it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.), thereby synthesizing molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling processes. Its key activity is high targeting and high affinity, and its core function is to be coupled with bifunctional chelators (such as DOTA, DATA5m) as a targeting module. NH2-UAMC1110 can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .
|
-
- HY-150270A
-
|
|
P2X Receptor
Prostaglandin Receptor
NOD-like Receptor (NLR)
Caspase
Interleukin Related
|
Inflammation/Immunology
|
|
NP-1815-PX sodium is an orally active dual inhibitor of P2X4 and prostaglandin TP receptors, with an IC50 of 0.26 μM against human P2X4 receptors. NP-1815-PX sodium specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX sodium selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX sodium not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX sodium exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX sodium is used in studies related to asthma and inflammatory bowel disease (colitis) .
|
-
- HY-150270
-
|
|
Prostaglandin Receptor
P2X Receptor
NOD-like Receptor (NLR)
Caspase
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
NP-1815-PX is an orally active dual inhibitor of P2X4 and prostaglandin TP receptors, with an IC50 of 0.26 μM against human P2X4 receptors. NP-1815-PX specifically inhibits ATP-mediated prostaglandin production, TP receptor-induced calcium elevation, and the canonical/non-canonical NLRP3 inflammasome signaling pathway. NP-1815-PX selectively blocks smooth muscle contractions induced by ATP, U46619 (HY-108566) and prostaglandin F2α. NP-1815-PX not only produces anti-allodynic effects in vivo, but also significantly alleviates symptoms of DNBS (HY-W324435)-induced colitis (such as weight loss and tissue damage). NP-1815-PX exerts anti-inflammatory effects by downregulating IL-1β levels and Caspase-1 activity. NP-1815-PX is used in studies related to asthma and inflammatory bowel disease (colitis) .
|
-
- HY-182361
-
|
|
AMPK
JAK
Cadherin
|
Cancer
|
|
NUAK1-IN-3 is a potent and selective NUAK1 inhibitor with an IC50 of 0.49 nM. NUAK1-IN-3 also inhibits NUAK2 and JAK3 with IC50 values of 265 and 225 nM. NUAK1-IN-3 engages Glu139 of NUAK1, forms a salt bridge between its bicyclic ring nitrogen and Asp142, and uses a fluorine atom to enhance hydrophobic binding interactions. NUAK1-IN-3 attenuates MYPT1 phosphorylation, suppresses the NUAK1-MYPT1 signaling axis, and inhibits proliferation, migration, and invasion of triple-negative breast cancer cells. NUAK1-IN-3 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT) marker alterations, downregulates Snail and N-cadherin, and upregulates E-cadherin in tumor tissues. NUAK1-IN-3 suppresses tumor growth in triple-negative breast cancer xenograft models. NUAK1-IN-3 can be used for the research of triple-negative breast cancer .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D0053
-
|
6-Carboxy-X-rhodamine
|
Fluorescent Dye
|
|
6-ROX is a selective fluorescent probe and potential inhibitor of COX-2. 6-ROX binds to the active site of COX-2 and inhibits its conversion of arachidonic acid into prostaglandins. 6-ROX is often used in the field of optical imaging related to tumors and inflammation, and helps detect diseased tissues with high expression of COX-2 .
|
-
- HY-D0163
-
|
|
Fluorescent Dye
|
|
Methyl Green is a non-intercalating fluorescent labeling agent that selectively binds to the major groove of DNA. Methyl Green electrostatically interacts with the major groove of DNA through positively charged groups, exhibiting key activities such as high affinity, resistance to photobleaching, and stable fluorescence emission. Methyl Green can be directly measured by microscopy and flow cytometry, with peaks at 633 and 677 nm. Methyl Green can be used for fluorescent labeling of the nuclei of embryonic tissues or cells, or DNA staining and cell activity detection in gel electrophoresis[1][2][3].
|
-
- HY-D2186
-
|
|
Fluorescent Dye
|
|
BTD probe-1 is a benzothiazine-based chemoproteomic probe and selective protein S-sulfenic acid (Cys-SOH) labeling agent. BTD probe-1 labels protein S-sulfenic acids in vitro in cell and tissue samples, and in situ in intact cells, enabling detection or enrichment of modified proteins/peptides. BTD probe-1 exhibits no cytotoxicity in cells at concentrations ≤1 mM. BTD probe-1 enables global, site-specific mapping and quantification of cysteine S-sulfenylation in complex proteomes with lower input material .
|
-
- HY-130013
-
|
|
Fluorescent Dye
|
|
HKYellow-AM (6/12-mixture) is a yellow fluorescent probe that can detect ONOO- in living cells and tissues with high selectivity and sensitivity without cytotoxicity .
|
-
- HY-D1275
-
|
|
Fluorescent Dye
|
|
CAY10731 (compound 3) is a highly selective fluorescent probe for detection of hydrogen sulfide (H2S). CAY10731 is used to monitor exo- and endogenous H2S in both cancer and normal cells. CAY10731 is applied for imaging of H2S in living tissues at variable depths and in nematodes .
|
-
- HY-D3267
-
|
|
Fluorescent Dye
|
|
ACu1 is a copper (I)-selective two-photon fluorescent probe that enables the visual imaging of Cu + distribution in living cells and tissues .
|
-
- HY-W713888
-
|
|
Fluorescent Dye
|
|
Aniline blue diammonium is a component of commonly used polychrome stains. Aniline blue diammonium is used to stain collagen fibers in tissue sections using Masson′s trichrome protocol for staining multiple components. Collagen is stained blue by this method. The dye is suitable for selective staining of callose in plant specimens and staining histones for assessing nuclear maturity. Aniline blue diammonium is used in Gomori′s one-step trichrome stain and Mallory′s connective tissue stain for tissue including kidney and intestine.
|
-
- HY-D3247
-
|
|
Fluorescent Dye
|
|
Cobalt (II) plant dye (Compound 3) is a Cobalt (II) probe. Cobalt (II) plant dye is used for the selective detection of bioaccumulated Cobalt (II) ions in root and stem tissues of Hybanthus enneaspermus plants .
|
-
- HY-D3172
-
|
|
Fluorescent Dye
|
|
BD-105 is a glucagon-binding fluorescent probe with a Ka value of 13.3 μM. BD-105 exhibits changes in fluorescence intensity upon interaction with glucagon, and colocalizes with glucagon in cells and tissues. BD-105 is a selective cell stain that labels glucagon-secreting cells without staining insulin-secreting cells or non-endocrine control cells. BD-105 serves as an imaging reagent for glucagon in live cells and tissues .
|
-
- HY-D3211
-
|
|
Fluorescent Dye
|
|
HJTA is a selective, pH/GSH dual-responsive Fluorescent probe and anticancer agent. HJTA selectively undergoes an enzymatic reaction with GSTπ. HJTA induces Apoptosis and Autophagy by regulating the expression of apoptotic and autophagic proteins. HJTA exhibits pH- and GSH-dual-responsive fluorescence in tumor cells. HJTA selectively illuminates tumor tissues, enabling precise in situ visualization of colon tumors. HJTA exerts anticancer effects against colon cancer. HJTA can be used for colon cancer research .
|
-
- HY-D2973
-
|
|
Fluorescent Dye
|
|
YH-APN is a high-performance APN activated near-infrared fluorescent probe. YH-APN has high sensitivity, high selectivity, fast response, and can achieve extremely high tumor/normal tissue signal-to-noise ratio through in situ spraying. YH-APN can specifically distinguish cancer cells with high expression of APN from normal cells and monitor the migration of cancer cells .
|
-
- HY-D3179
-
|
|
Fluorescent Dye
|
|
CDg13 is a fluorescent probe that specifically detects living neural stem/progenitor cells. CDg13 localizes to the endoplasmic reticulum via its dihexyl moiety, with no interaction with endoplasmic reticulum biomolecules. CDg13 undergoes selective efflux by active ABCG2 transporters, with increased intracellular accumulation following ABCG2 inhibition or knockdown. CDg13 isolates and enriches self-renewable neural stem/progenitor cells from embryonic mouse brain tissue, stains neural stem/progenitor cells brightly, and sorts ABCG2low cell populations from heterogeneous populations . (Ex/Em = 520/553 nm)
|
-
- HY-D3190
-
|
|
Fluorescent Dye
|
|
BODIPY-DOX is a conjugate composed of BODIPY and Doxorubicin (HY-15142A), as well as a pH-activated fluorescent probe for M1 macrophages and an apoptosis inducer. BODIPY-DOX undergoes pH-induced hydrazone bond cleavage in acidic M1 macrophage phagosomes, thereby releasing cytotoxic Doxorubicin (Dox) and inhibiting the function of pro-inflammatory M1 macrophages. BODIPY-DOX highly selectively inhibits the production of relevant pro-inflammatory cytokines by mouse and human monocyte-derived M1 macrophages, while exerting minimal effects on M2 or unactivated macrophages. Therefore, BODIPY-DOX enables simultaneous fluorescent tracing, differentiation and elimination of specific macrophage subsets, and exhibits the potential to regulate tissue regeneration in zebrafish models .
|
| Cat. No. |
Product Name |
Type |
-
- HY-Y1147
-
|
Maleic acid diethyl ester
|
Biochemical Assay Reagents
|
|
Diethyl maleate (DEM) is an orally available, effective glutathione (GSH) depletor that crosses the blood-brain barrier. Diethyl maleate covalently binds irreversibly to GSH via glutathione S-transferase with an in vitro IC50 of 0.1-0.5 mM. Diethyl maleate selectively depletes GSH in liver, lung, and brain tissues, exacerbating oxidative stress and enhancing hyperbaric oxygen toxicity. Diethyl maleate promotes precursor amino acid uptake and in turn promotes GSH synthesis by upregulating the activity of the cystine-glutamate transporter XO -. Diethyl maleate can be used to study redox homeostasis and GSH protection mechanisms in oxidative stress-related diseases such as hyperbaric oxygen injury and metabolic diseases[1][2][3].
|
-
- HY-W087830
-
|
L-BPA
|
Biochemical Assay Reagents
|
|
L-p-Boronophenylalanine is a boron-containing substrate for L-type amino acid transporters (LAT1 and LAT2). L-p-Boronophenylalanine enters tumor cells by competing with natural amino acids for LAT, selectively accumulating boron in cancer cells. L-p-Boronophenylalanine can be used in boron neutron capture therapy (BNCT). When boron-10 captures thermal neutrons, a nuclear reaction occurs, producing high-energy alpha particles and lithium nuclei, which kill cancer cells at close range with little damage to surrounding tissues. L-p-Boronophenylalanine can be used in cancer research, especially glioblastoma and anaplastic astrocytoma .
|
-
- HY-W068119A
-
|
2-Maleimidoethylamine hydrochloride
|
Biochemical Assay Reagents
|
|
N-(2-Aminoethyl)maleimide (2-Maleimidoethylamine) hydrochloride is a selective covalent binding agent for thiol groups (RSGs), covalently binding to thiols via an irreversible thioether bond to prepare MMP-2-sensitive nanosystems. Under near-neutral conditions, the maleimide group in N-(2-Aminoethyl)maleimide hydrochloride binds to thiol groups via a nucleophilic addition reaction, and can be used to modify polymers or biological interfaces, enhancing mucosal adhesion and regulating the surface charge of biological interfaces. N-(2-Aminoethyl)maleimide hydrochloride can optimize the adhesion performance of drug delivery carriers and cell interactions with biological interfaces, and is applied in transmucosal drug delivery systems (such as drug carriers for oral and bladder sites) and biomaterial surface engineering research, providing support for tissue implantation, regeneration, and related drug delivery .
|
-
- HY-NP002D
-
|
|
Biochemical Assay Reagents
|
|
Bovine Serum Albumin (Biotinylated) is a biotinylated bovine serum albumin that selectively binds to different vascular subsets in lymphoid tissue. Bovine Serum Albumin (Biotinylated) can be used as a histochemical probe, and a targeting ligand for drug delivery .
|
-
- HY-W116336D
-
|
|
Biochemical Assay Reagents
|
|
Zinc oxide, <100 nm particle size is a nitrate reductase modulator and growth promoter with plant stress resistance activity and oral toxicity. Zinc oxide, <100 nm particle size acts as a nutrient source for maize plants. By enhancing nitrate reductase activity and reducing free proline levels, it significantly improves plant height, root length and dry matter weight of maize, and its growth-promoting effect is comparable to that of traditional zinc sulfate fertilizer. Zinc oxide, <100 nm particle size induces anemia-related and persistent tissue inflammatory damage, leading to obvious histopathological adverse reactions in the stomach, pancreas, eyes and prostate of rats. Zinc oxide, <100 nm particle size acts as a non-toxic antibacterial agent and selective cytotoxin against multiple bacteria, fungi and spores .
|
-
- HY-W009411
-
|
|
Biochemical Assay Reagents
|
|
Dansyl hydrazine is a carbohydrate-specific fluorescent dye (Ex/Em = 340 nm/525 nm). Dansyl hydrazine undergoes a condensation reaction with aldehyde groups generated by periodate oxidation on carbohydrate-containing structures to form fluorescent hydrazone compounds. Dansyl hydrazine selectively stains polysaccharides in formalin-fixed, paraffin-embedded human post-mortem brain tissues, revealing detailed structural features. Dansyl hydrazine is applicable to research related to Alzheimer's disease, Lafora disease, and polyglucosan body disease .
|
-
- HY-172687A
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG3400-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG3400-CSTSMLKAC can be used for drug delivery .
|
-
- HY-172688
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG5000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG5000-CSTSMLKAC can be used for drug delivery .
|
-
- HY-172686
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG1000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG1000-CSTSMLKAC can be used for drug delivery .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4744
-
|
|
Formyl Peptide Receptor (FPR)
Bacterial
|
Infection
Cancer
|
|
LL-37 amide is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED99=8.5-8.7 μg/mL). LL-37 amide exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .
|
-
- HY-P1821
-
|
MHP4-14
|
PKC
|
Neurological Disease
|
|
Myelin Basic Protein (MHP4-14), a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .
|
-
- HY-P10709
-
|
|
Collagen
|
Cardiovascular Disease
Cancer
|
|
CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects .
|
-
- HY-P1116
-
PBP10
1 Publications Verification
|
Bacterial
Reactive Oxygen Species (ROS)
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
PBP10 is a decapeptide. PBP10 selectively binds to lipoteichoic acid (LTA), lipopolysaccharide (LPS) and phosphatidylinositol-4,5-bisphosphate (PIP2). PBP10 penetrates cell membranes and possesses bactericidal, anti-inflammatory, cell motility-inhibiting and actin assembly-regulating activities. PBP10 is applicable to relevant research on bacterial infections, microbe-induced inflammation, skin and soft tissue infections, as well as sepsis .
|
-
- HY-P10216
-
|
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
CAQK peptide selectively binds to injured mouse brain. CAQK peptide selectively targets demyelinating areas and it is absent from healthy tissue. The CAQK peptide target is a proteoglycan complex upregulated in brain injuries and is used for drug delivery. CAQK peptide can penetrate the blood-brain barrier .
|
-
- HY-P3849
-
|
LMN-NKA
|
Neurokinin Receptor
|
Neurological Disease
|
|
[Lys5,MeLeu9,Nle10]Neurokinin A(4-10) (LMN-NKA), an analogue of Neurokinin A, is a selective and potent NK2R agonist. [Lys5,MeLeu9,Nle10]Neurokinin A(4-10) has prokinetic activity. [Lys5,MeLeu9,Nle10]Neurokinin A(4-10) can be used to study the roles of the NK-2 receptor in smooth muscle contraction in numerous tissues .
|
-
- HY-P4744A
-
|
|
Formyl Peptide Receptor (FPR)
Bacterial
|
Infection
Cancer
|
|
LL-37 amide TFA is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens (ED99=8.5-8.7 μg/mL). LL-37 amide TFA exerts its bactericidal effect by activating FPRL1-mediated immune cell chemotaxis and disrupting bacterial cell membrane integrity. It can also regulate inflammatory responses (inhibiting the release of factors such as TNF-α) and promote angiogenesis. Amidation modification reduces its sensitivity to serum inhibition and improves its stability. LL-37 amide TFA possesses key activities in bactericidal action, immunomodulation, and wound healing, and is mainly used in research on infection-related diseases such as periodontal disease and deep tissue injuries (pressure ulcers), and wound healing .
|
-
- HY-P1130
-
|
Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
M871 (Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide) is an orally active and selective galanin receptor type 2 (GalR2) antagonist. M871 exhibits Ki values of 13.1 nM, 420 nM and >10 μM for GalR2, GalR1 and GalR3 respectively. M871 relieves the mice allergic rhinitis by reducing IgE production, as well as the number of B cells in tissues. M871 can inhibit the nerve invasion of salivary adenoid cystic carcinoma (SACC) and alleviate myocardial ischemia-reperfusion injury. M871 can be used for research on GalR2-related diseases (such as epilepsy, pain) .
|
-
- HY-P1473
-
|
Amylin (8-37) (mouse, rat)
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (8-37), rat is a truncated analog of native Amylin that selectively inhibits insulin-related glucose uptake and glycogen deposition in muscle tissue. Amylin (8-37), rat is a weak amylin receptor (AMY) antagonist.
|
-
- HY-P5421
-
|
|
Proton Pump
|
Others
|
|
Caloxin 1B1 is a biological active peptide. (Caloxin 1b1 is obtained by screening for binding to extracellular domain 1 of PMCA4, which inhibited PMCA extracellularly, selectively, and had a higher affinity for PMCA4 than PMCA1. Because caloxin 1b1 had been selected to bind to an extracellular domain of PMCA, it could be added directly to cells and tissues to examine its effects on smooth muscle and endothelium.)
|
-
- HY-P1116A
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
PBP10 TFA is a decapeptide. PBP10 TFA selectively binds to lipoteichoic acid (LTA), lipopolysaccharide (LPS) and phosphatidylinositol-4,5-bisphosphate (PIP2). PBP10 TFA penetrates cell membranes and possesses bactericidal, anti-inflammatory, cell motility-inhibiting and actin assembly-regulating activities. PBP10 TFA is applicable to relevant research on bacterial infections, microbe-induced inflammation, skin and soft tissue infections, as well as sepsis .
|
-
- HY-P1106A
-
|
|
CFTR
|
Cardiovascular Disease
|
|
K41498 TFA is a highly selective CRF 2 receptor antagonist, with a Ki of 0.66 nM for human CRF2α receptor and a Ki of 0.62 nM for human CRF2β receptor. K41498 TFA inhibits cAMP accumulation in cells expressing CRF2. K41498 TFA antagonizes the hypotensive response induced by systemic administration of urocortin in conscious rats. K41498 TFA undergoes radioiodination without loss of activity and serves for autoradiographic studies of native CRF2 receptors in rat brain and peripheral tissues .
|
-
- HY-P10420
-
|
|
CD47
Interleukin Related
|
Cancer
|
|
RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape .
|
-
- HY-P1821A
-
|
MHP4-14 TFA
|
PKC
|
Neurological Disease
|
|
Myelin Basic Protein (MHP4-14) TFA, a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein TFA is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .
|
-
- HY-P1106
-
|
|
CRFR
|
Cardiovascular Disease
|
|
K41498 is a highly selective CRF 2 receptor antagonist, with a Ki of 0.66 nM for human CRF2α receptor and a Ki of 0.62 nM for human CRF2β receptor. K41498 inhibits cAMP accumulation in cells expressing CRF2. K41498 antagonizes the hypotensive response induced by systemic administration of urocortin in conscious rats. K41498 undergoes radioiodination without loss of activity and serves for autoradiographic studies of native CRF2 receptors in rat brain and peripheral tissues .
|
-
- HY-P5640
-
|
|
Bacterial
Parasite
|
Infection
|
|
Tritrpticin is a porcine-derived antimicrobial peptide with properties such as membrane disruption and hemolysis. Tritrpticin disrupts the cell membranes of bacteria, fungi and Jurkat T cell leukemia cells and induces their death. Tritrpticin also enhances the efficacy of Metronidazole (HY-B0318) against *Trichomonas vaginalis*, reduces plasma endotoxin and inflammatory cytokine levels, restricts bacterial growth in blood and visceral tissues, decreases the mortality rate of septic shock in rats and enhances the therapeutic effect of ertapenem. Tritrpticin exhibits selective cytotoxicity against Jurkat T cell leukemia cells, while showing low toxicity to normal peripheral blood mononuclear cells and red blood cells, and can serve as a template for antimicrobial peptide design. Tritrpticin can be applied to research related to bacterial infections, fungal infections, trichomoniasis, septic shock and leukemia .
|
-
- HY-P11049
-
|
|
Peptides
|
Neurological Disease
|
|
Stroke-homing peptide is a homing peptide. Stroke-homing peptide can home to ischemic stroke brain tissue and detect the apoptotic neuronal cells. Stroke-homing peptide can be used for the research of molecular imaging and selective drug delivery to stroke tissue .
|
-
- HY-159771
-
|
|
FAP
|
Cancer
|
|
FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
|
-
- HY-P11578
-
|
|
Peptides
|
Metabolic Disease
|
|
CKGGRAKDC (linear) is an adipose tissue homing peptide. CKGGRAKDC (linear) binds to vasculature-enriched prohibitin in adipose tissue to enable selective tissue targeting. CKGGRAKDC (linear) can be used to selective delivery of cargos to adipose tissues .
|
-
- HY-P11578A
-
|
|
Peptides
|
Metabolic Disease
|
|
CKGGRAKDC (linear) TFA is an adipose tissue homing peptide. CKGGRAKDC (linear) TFA binds to vasculature-enriched prohibitin in adipose tissue to enable selective tissue targeting. CKGGRAKDC (linear) TFA can be used to selective delivery of cargos to adipose tissues .
|
-
- HY-P11590
-
|
|
EGFR
|
Cancer
|
|
WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a KD of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .
|
-
- HY-P0036D
-
|
|
Drug Derivative
Radionuclide-Drug Conjugates (RDCs)
Somatostatin Receptor
Apoptosis
|
Cancer
|
|
NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors. .
|
-
- HY-P11618
-
|
|
Glycoprotein VI
|
Cancer
|
|
10P3Me is a Glypican-3 (GPC3)-targeting probe with a Ka of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for PET imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P99575
-
|
AMG-757
|
Notch
|
Inflammation/Immunology
Cancer
|
|
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
|
-
(5)
-
- HY-P990301
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is a mouse-derived IgG2b λ type antibody inhibitor, targeting to Amyloid-beta. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) recognizes unaggregated, oligomeric or fibrillar forms of Aβ42 and unaggregated Aβ40. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is selective for human Aβ42 over Aβ40, but not amyloid precursor protein (APP). Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can immunostain human or rat and mouse tissue. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can be used for detections of western blot, immunohistochemistry, immunofluorescence, immunoprecipitation and ELISA .
|
-
(5)
-
- HY-P991950
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
SHR-1906 is a selective fully humanized monoclonal IgG1 inhibitory antibody targeting CTGF. SHR-1906 specifically binds to CTGF, thereby blocking the interaction between CTGF and TGF-B1 with an inhibition rate of 55%. SHR-1906increases the survival rate in a pulmonary fibrosis model by reducing TGF-β1 levels and inhibiting fibrotic lesions in lung tissue in Bleomycin (HY-108345)-induced pulmonary fibrosis.SHR-1906 can be used for pulmonary fibrosis (IPF) research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-13738A
-
-
-
- HY-B1614
-
-
-
- HY-N2909
-
-
-
- HY-N0457A
-
-
-
- HY-N3945
-
|
O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396
|
Infection
Alkaloids
other families
Classification of Application Fields
Plants
Isoquinoline Alkaloids
Glaucium flavum
Inflammation/Immunology
Disease Research Fields
Papaveraceae
Source Classification
|
Phosphodiesterase (PDE)
Calcium Channel
MMP
NF-κB
|
|
Glaucine (O,O-Dimethylisoboldine) is an alkaloid extracted from Glaucium flavum that possesses various activities, including cough relief, bronchodilation, anti-inflammatory effects, analgesia, antipyretic properties, and anticancer effects. Glaucine acts as a selective and orally active inhibitor of phosphodiesterase 4 (PDE4), with a Ki of 3.4 µM in human bronchial tissues and polymorphonuclear leukocytes. Glaucine induces relaxation of human isolated bronchi by antagonizing calcium channels. Additionally, Glaucine inhibits the activation of NF-κB, leading to a reduction in the expression of the MMP-9 gene, thereby suppressing the migration and invasion of breast cancer cells. Therefore, Glaucine holds potential for research in asthma and breast cancer .
|
-
-
- HY-116330
-
-
-
- HY-13738AR
-
-
-
- HY-N9141
-
-
-
- HY-N0457AR
-
-
-
- HY-B1614R
-
-
-
- HY-N9980
-
|
|
Structural Classification
Microorganisms
Steroids
Source Classification
|
PI3K
Akt
NF-κB
p38 MAPK
AP-1
|
|
Antcin K is a selective inhibitor targeting the PI3K/Akt, NF-κB, MEK1/2-ERK, p38 and AP-1 pathways. Antcin K upregulates IL-10 expression, thereby inhibiting the production of pro-inflammatory factors, blocking monocyte adhesion, reducing tissue damage, and promoting myogenesis. Antcin K has significant anti-inflammatory, anti-damage and tissue protective activities. Antcin K is mainly used in the research of inflammation-related diseases such as periodontitis, rheumatoid arthritis, and skeletal muscle injury .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-18572S2
-
|
|
|
2,4-D-d5 (2,4-Dichlorophenoxyacetic acid-d5) is the deuterium labeled 2,4-D (HY-18572) . 2,4-D (2,4-Dichlorophenoxyacetic acid) is a selective systemic herbicide for the control of broad-leaved weeds. 2,4-D acts as a plant hormone, causing uncontrolled growth in the meristematic tissues. 2,4-D inhibits DNA and protein synthesis and thereby prevents normal plant growth and development .
|
-
-
- HY-18572S
-
|
|
|
2,4-D- 13C6 is the 13C-labeled 2,4-D (HY-18572). 2,4-D (2,4-Dichlorophenoxyacetic acid) is a selective systemic herbicide for the control of broad-leaved weeds. 2,4-D acts as a plant hormone, causing uncontrolled growth in the meristematic tissues. 2,4-D inhibits DNA and protein synthesis and thereby prevents normal plant growth and development .
|
-
-
- HY-119649S
-
|
|
|
Flonicamid- 15N,18O (IKI220- 15N,18O) is 15N labeled Flonicamid. Flonicamid (IKI220) is a novel systemic insecticide with selective activity against hemipterous pests. The main insecticidal mechanism of flonicamid is starvation based on the inhibition of stylet penetration to plant tissues .
|
-
-
- HY-B1398S
-
|
|
|
Ampyrone-d3 is the deuterium labeled Ampyrone (HY-B1398). Ampyrone (4-Aminophenazone; 4-Aminoantipyrine) is a reversible and low-damage optical clearing agent and non-selective COX inhibitor based on UV absorption properties. Ampyrone can improve the optical transmittance of mouse skin and other tissues. Ampyrone can induce tissue refractive index matching by enhancing UV absorption, reduce light scattering, and achieve tissue transparency in vivo. Ampyrone reduces the synthesis of prostaglandin PGE2, thereby exerting anti-inflammatory, analgesic and antipyretic effects. Ampyrone inhibits DNA damage, cell apoptosis and immune cell phagocytosis induced by Doxorubicin (HY-15142A) and Cisplatin (HY-17394), etc., and participates in the regulation of toxicity in tumor chemotherapy .
|
-
-
- HY-18572S1
-
|
|
|
2,4-D-d3 is the deuterium labeled 2,4-D (HY-18572) . 2,4-D (2,4-Dichlorophenoxyacetic acid) is a selective systemic herbicide for the control of broad-leaved weeds. 2,4-D acts as a plant hormone, causing uncontrolled growth in the meristematic tissues. 2,4-D inhibits DNA and protein synthesis and thereby prevents normal plant growth and development .
|
-
-
- HY-10569S
-
|
|
|
Ponesimod-d4 (ACT-128800-d4) is the deuterium labeled Ponesimod (HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .
|
-
-
- HY-10569S1
-
|
|
|
Ponesimod-d7 (ACT-128800-d7) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d7 (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod-d7 activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod-d7 can protect against lymphocyte-mediated tissue inflammation .
|
-
-
- HY-W009411S
-
|
|
|
Dansyl hydrazine- 13C2 is the 13C-labeled Dansyl hydrazine (HY-W009411). Dansyl hydrazine is a carbohydrate-specific fluorescent dye (Ex/Em = 340 nm/525 nm). Dansyl hydrazine undergoes a condensation reaction with aldehyde groups generated by periodate oxidation on carbohydrate-containing structures to form fluorescent hydrazone compounds. Dansyl hydrazine selectively stains polysaccharides in formalin-fixed, paraffin-embedded human post-mortem brain tissues, revealing detailed structural features. Dansyl hydrazine is applicable to research related to Alzheimer's disease, Lafora disease, and polyglucosan body disease.
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-158821A
-
|
|
|
Antisense Oligonucleotides
|
|
ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases .
|
-
- HY-158821
-
|
|
|
Antisense Oligonucleotides
|
|
ISTH0036 is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases .
|
-
- HY-172687A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG3400-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG3400-CSTSMLKAC can be used for drug delivery .
|
-
- HY-172688
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG5000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG5000-CSTSMLKAC can be used for drug delivery .
|
-
- HY-172686
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-CSTSMLKAC is a PEG compound which composed of DSPE and a peptide (CSTSMLKAC). CSTSMLKAC is capable of mediating selective homing of phage to ischemic heart tissue. DSPE-PEG1000-CSTSMLKAC can be used for drug delivery .
|
-
- HY-158821B
-
|
|
|
Antisense Oligonucleotides
|
|
ISTH0036 sodium scrambled negative control is the sequence scrambled negative control of ISTH0036 sodium (HY-158821A). ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases.
|
-
- HY-158821D
-
|
|
|
Antisense Oligonucleotides
|
|
Cy3 labled ISTH0036 sodium is a Cy3 labled ISTH0036 sodium (HY-158821A). ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases.
|
-
- HY-158821C
-
|
|
|
Antisense Oligonucleotides
|
|
FAM labled ISTH0036 sodiumis a FAM labled ISTH0036 sodium (HY-158821A). ISTH0036 sodium is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 sodium suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 sodium exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 sodium can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![[Lys5,MeLeu9,Nle10]Neurokinin A(4-10)](http://file.medchemexpress.com/product_pic/hy-p3849.gif)
